

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
9 August 2007 (09.08.2007)

PCT

(10) International Publication Number
WO 2007/089507 A1

(51) International Patent Classification:

A61K 31/4745 (2006.01) A61P 37/00 (2006.01)
A61K 31/00 (2006.01) C07D 471/04 (2006.01)
A61P 35/00 (2006.01)

Kenneth [US/US]; 11218 Watermill Lane, Silver Spring,
MD 20902 (US).

(21) International Application Number:

PCT/US2007/001930

(74) Agents: NATH, Gary, M. et al.; THE NATH LAW
GROUP, 112 S. West Street, Alexandria, VA 22314 (US).

(22) International Filing Date: 25 January 2007 (25.01.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/762,141 26 January 2006 (26.01.2006) US

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS,
JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS,
LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY,
MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS,
RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(71) Applicants (for all designated States except US): **THE
GOVERNMENT OF THE UNITED STATES OF
AMERICA, represented by THE SECRETARY,
DEPT. OF HEALTH AND HUMAN SERVICES**
[US/US]; National Institutes of Health Office of Tech-
nology Transfer, 6011 Executive Boulevard, Suite 325,
Rockville, MD 20852-3804 (US). **UNIVERSITEIT
LEIDEN** [NL/NL]; Gorlaeus Laboratories, Einsteinweg
55, NL-2333 CC Leiden (NL).

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT,
RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **GOBLYOS, Aniko**
[HU/NL]; Savelsbos 144, NL-2716 HG Zoetermeer (NL).
BRUSSEE, Johannes [NL/NL]; Prins Bernhardlaan 11,
NL-2231 VJ Rijnsburg (NL). **IJZERMAN, Adriaan, P.**
[NL/NL]; Park Oosterspaam 6, NL-2036 MB Haarlem
(NL). **GAO, Zhan-Guo** [CN/US]; 13211 Twinbrook
Parkway, #104, Rockville, MD 20851 (US). **JACOBSON,**

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: A₃ ADENOSINE RECEPTOR ALLOSTERIC MODULATORS

(57) Abstract: The present invention relates to allosteric modulation of A₃ adenosine receptor (A₃AR) and provides for the use of an A₃ adenosine receptor modulator (A₃RM), for the preparation of pharmaceutical compositions for modulating the A₃AR in a subject, as well as pharmaceutical compositions comprising the same and therapeutic methods comprising administering to a subject an amount of an A₃RM, the amount being effective to modulate A₃AR activity. The A₃RM according to the invention are 1H-Imidazo-[4,5-c]quinolin-4-amine derivatives. The invention also provides some of such novel 1H-Imidazo-[4,5-c]quinolin-4-amine derivatives.

WO 2007/089507 A1

A₃ ADENOSINE RECEPTOR ALLOSTERIC MODULATORS

FIELD OF THE INVENTION

This invention relates to A₃ adenosine receptor (A₃AR) allosteric modulators and uses thereof.

PRIOR ART

The following is a list of prior art which is considered to be pertinent for describing the state of the art in the field of the invention. Acknowledgement of these references herein will at times be made by indicating their number within brackets from the list below.

1. Fishman P, et al. Evidence for involvement of Wnt signaling pathway in IB-MECA mediated suppression of melanoma cells. *Oncogene*, **21**:4060-4064 (2002).
2. Fishman P, et al. Targeting the A₃ adenosine receptor for cancer therapy: inhibition of Prostate carcinoma cell growth by A₃AR agonist. *Anticancer Res.*, **23**:2077-2083 (2003).
3. Madi L, et al. A₃ adenosine receptor activation in melanoma cells: association between receptor fate and tumor growth inhibition. *J. Bio. Chem.*, **278**:42121-42130 (2003).
4. Ohana G, et al. Inhibition of primary colon carcinoma growth and liver metastasis by the A₃ adenosine receptor agonist IB-MECA. *British J. Cancer.*, **89**:1552-1558 (2003).
5. Fishman P, et al. An agonist to the A₃ adenosine receptor inhibits colon carcinoma growth in mice via modulation of GSK-3 β and NF- κ B. *Oncogene*, **23**:2465-2471 (2004).
6. US Patent Application No. 2004016709 A1.

- 2 -

7. Szabo, C., et al. Suppression of macrophage inflammatory protein (MIP)-1 α production and collagen-induced arthritis by adenosine receptor agonists. *British J. Pharmacology*, **125**:379-387 (1998).
8. Mabley, J., et al. The adenosine A₃ receptor agonist, N⁶-(3-iodobenzyl)-adenosine -5'-N-methyluronamide, is protective in two murine models of colitis. *Europ. J. Pharmacology*, **466**:323-329 (2003).
9. Baharav, E., et al. The effect of adenosine and the A₃ adenosine receptor agonist IB-MECA on joint inflammation and autoimmune diseases models. *Inter. J. Mol. Med.* **10**(supplement 1) page S104, abstract 499 (2002).
10. PCT Application, publication No. WO2005/0063246, entitled "Method for Treatment of Multiple Sclerosis".
11. Montesinos, M. Carmen, et al. Adenosine A_{2A} or A₃ receptors are required for inhibition of inflammation by methotrexate and its analog MX-68. *Arthritis & Rheumatism*, **48**:240-247 (2003).
12. Madi L, et al. The A₃ Adenosine Receptor is Highly Expressed in Tumor vs. Normal Cells: Potential Target for Tumor Growth Inhibition. *Clinical Cancer Research*, **10**: 4472-4479 (2004).
13. US Patent Application, publication No. 20040137477 A1, entitled "A3AR as a marker for a diseased state".
14. Gessi, S. et al. Elevated expression of A₃ adenosine receptors in human colorectal cancer is reflected in peripheral blood cells *Clinical Cancer Research* **10**:5895-5901 (2004).
15. Birdsall NJ et al., Allosteric regulation of G-protein-linked receptors *biochem Soc Trans* **23**:108-111 (1995).
16. Holzgrave U and Mohr K, Allosteric modulators of ligand binding to muscarinic acetylcholine receptors, *Drug Disc Today* **3**:214-222 (1998).
17. Bruns RF and Fergus JH, Allosteric enhancement of adenosine A₁ receptor binding and function by 2-amino-3-benzoylthiophenes, *Mol Pharmacol* **38**:939-949 (1990).

- 3 -

18. Gao ZG and IJerman AP, Allosteric modulation of A_{2A} adenosine receptors by amiloride analogues and sodium ions, *Biochem Pharmacol* **60**:669-676 (2000).

19. Gao ZG, Jiang Q, Jacobson KA, and IJerman AP, Site-directed mutagenesis studies of human A_{2A} adenosine receptors. Involvement of Glu¹³ and His²⁷⁸ in ligand binding and sodium modulation, *Biochem Pharmacol* **60**:661-668 (2000).

20. Gao ZG, Kin SG, Soltysiak KA, Melman N, IJerman AP, Jacobson KA, Selective allosteric enhancement of agonist binding and function at human A₃ Adenosine receptors by a series of imidazoquinoline derivatives, *Mol Pharmacol* **62**:81-89 (2002).

BACKGROUND OF THE INVENTION

G protein-coupled receptors (GPCRs) class is the largest family of cell-surface receptors which plays a crucial role in intracellular signal transduction. Adenosine receptors are part of the GPCR class, which belongs to the Class A or rhodopsin-like subfamily of GPCRs. Adenosine, a purine nucleoside, produces numerous physiological actions via cell surface adenosine receptors. These receptors are widely distributed throughout the body and are divided into four subclasses, A₁, A_{2A}, A_{2B} and A₃ receptors, the latter being the most recently identified receptor.

The A₃ adenosine receptor (A₃AR) is involved in a variety of physiological processes. The receptor is highly expressed in various tumor cell types while expression in adjacent normal tissues is relatively low. Activation of the receptor by a specific synthetic agonist induces modulation of downstream signal transduction pathways which include the Wnt and the NF- κ B, resulting in tumor growth inhibition (1-5).

In vivo studies have shown that A₃AR agonists inhibit the development of colon, prostate and pancreatic carcinomas as well as melanoma and hepatoma. A₃AR agonists were also been shown to act as anti-inflammatory agents by ameliorating the inflammatory process in different experimental autoimmune models such as rheumatoid arthritis, Crohn's disease and multiple sclerosis (6-10). It was proposed also that the A_{2A} and A₃ receptors mediate the anti-inflammatory effects of methotrexate (11).

A₃ adenosine receptor (A₃AR) expression levels are elevated in cancer cells as compared to normal cells (12). Thus, the A₃AR expression level has been described as a

- 4 -

means for the diagnosis of cancer (13). In addition, A₃AR expression levels have also been described to be elevated in peripheral blood cells of patients with colorectal cancer (14).

Several members of the GPCR class of receptors have been reported to be modulated allosterically (15), i.e. these receptors have additional binding site(s) on a receptor that are distinct from the agonist binding site (orthosteric site, orthosterically modulated receptors), but that can modulate receptor activity.

Allosteric modulation of GPCRs has been characterized most extensively for muscarinic receptors (16), and it has been suggested that allosteric modulators may provide therapeutic advantages over orthosteric agonists. Such advantages may include greater subtype selectivity and fewer side effects (15).

The adenosine receptors are natural allosteric proteins because agonist-mediated signaling by GPCRs requires a conformational change in the receptor protein transmitted between two topographically distinct binding sites, one for the agonist and another for the G protein. Allosteric sites on GPCRs represent novel drug targets because allosteric modulators possess a number of advantages over classic orthosteric ligands, such as a ceiling level to the allosteric effect and a potential for greater GPCR subtype-selectivity.


Allosteric modulation of A₁ adenosine receptors was reported (17). A number of aminobenzoylthiophenes, including PD81723, were allosteric modulators of the A₁ adenosine receptor (19). These compounds were shown to be highly subtype-selective enhancers for A₁ adenosine receptors (19) and were less likely to cause desensitization and down-regulation of receptors than selective A₁ adenosine receptor agonists.

Some 1H-imidazo-[4,5-c]quinoline derivatives were described as selective allosteric enhancers of human A₃ adenosine receptors (20). Specifically, the derivatives were shown to potentiate the potency and maximal efficacy of agonist-induced responses while decreasing the dissociation of the agonist N⁶-(4-amino-3-[¹²⁵I]iodobenzyl)-5'-N-methylcarboxamidoadenosine from human A₃ adenosine receptors.

- 5 -

SUMMARY OF THE INVENTION

In accordance with the first aspect, the present invention provides the use of an A₃ adenosine receptor allosteric modulator (A₃RM) for the preparation of a pharmaceutical composition for the preparation of a pharmaceutical composition for the treatment of a condition which requires for said treatment modulation of A₃ adenosine receptor (A₃AR), wherein said A₃RM has the following general formula (I):



Formula I

wherein:

- **R₁** represents an aryl or alkaryl being optionally substituted once or more at the aromatic ring with a substituent selected C₁-C₁₀ alkyl, halo, C₁-C₁₀ alkanol, hydroxyl, C₁-C₁₀ acyl, C₁-C₁₀ alkoxy; C₁-C₁₀-alkoxycarbony, C₁-C₁₀ alkoxyalkyl; C₁-C₁₀ thioalkoxy; C₁-C₁₀ alkylether, amino, hydrazido, C₁-C₁₀ alkylamino, pyridylthio, C₂-C₁₀ alkenyl; C₂-C₁₀ alkynyl, thio, and C₁-C₁₀ alkylthio, acetoamido, sulfonic acid; or said substituents can form together a cycloalkyl or cycloalkenyl fused to said aryl, the cycloalkyl or cycloalkenyl optionally comprising one or more heteroatoms; provided that said aryl is not an unsubstituted phenyl group;
- **R₂** represents hydrogen or a substituent selected from C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl; C₂-C₁₀ alkynyl, C₄-C₁₀ cycloalkyl, C₄-C₁₀ cycloalkenyl, or a five to seven membered heterocyclic aromatic ring, C₅-C₁₅ bridged or fused cycloalkyl, bicyclic aromatic or heteroaromatic rings; or C₁-C₁₀ alkylether,

- 6 -

amino, hydrazido, C₁-C₁₀ alkylamino, C₁-C₁₀ alkoxy, C₁-C₁₀-alkoxycarbony, C₁-C₁₀ alkanol, C₁-C₁₀ acyl, C₁-C₁₀ thioalkoxy, pyridylthio, thio, and C₁-C₁₀ alkylthio, acetoamido, sulfonic acid.

and pharmaceutically acceptable salts thereof.

In accordance with a further aspect, there is also provide a method of modulating A₃ adenosine receptor (A₃AR) in a subject, the method comprises administering to said subject an amount of an A₃ adenosine receptor allosteric modulator (A₃RM), the amount being effective to modulate A₃AR activity,

In accordance with yet a further aspect, there is provided a method of treating a subject for a condition which requires for said treatment modulation of A₃ adenosine receptor (A₃AR), the method comprises administering to said subject an amount of an A₃ adenosine receptor allosteric modulator (A₃RM) having the general formula as defined above, the amount of the A₃RM being effective to modulate A₃AR activity.

The invention also provides a pharmaceutical composition for the treatment of a condition which requires for said treatment modulation of A₃ adenosine receptor (A₃AR), the composition comprises as active ingredient an A₃ adenosine receptor allosteric modulator (A₃RM), having the general formula (I) as defined above.

A preferred composition in accordance with the invention is in the form suitable for oral administration.

The A₃RM is preferably utilized in accordance with the invention for enhancing the A₃AR.

The present invention also provides imidazoquinoline derivatives having the general formula I as defined above, for use as an A₃AR allosteric enhancer.

The invention also provides imidazoquinoline derivatives selected from:

N-(4-Methyl-phenyl)-2-cyclopentyl-1H-imidazo[4,5-c]quinolin-4-amine (31)

N-(4-Methoxy-phenyl)-2-cyclopentyl-1H-imidazo[4,5-c]quinolin-4-amine (32)

N-(3,4-Dichloro-phenyl)-2-cyclopentyl-1H-imidazo[4,5-c]quinolin-4-amine (33)

N-(4-Chloro-phenyl)-2-cyclopentyl-1H-imidazo[4,5-c]quinolin-4-amine (34)

N-(3-Methanol-phenyl)-2-cyclopentyl-1H-imidazo[4,5-c]quinolin-4-amine (35)

N-([3,4-c]Indan)-2-cyclopentyl-1H-imidazo[4,5-c]quinolin-4-amine (36)

- 7 -

N-(1H-indazol-6-yl)-2-cyclopentyl-1H-imidazo[4,5-c]quinolin-4-amine (37)
N-(4-Methoxy-benzyl)-2-cyclopentyl-1H-imidazo[4,5-c]quinolin-4-amine (38)
N-(1H-Indol-6-yl)-2-cyclopentyl-1H-imidazo[4,5-c]quinolin-4-amine (39)
N-(Benzyl)-2-cyclopentyl-1H-imidazo[4,5-c]quinolin-4-amine (40)
N-(Phenylethyl)-2-cyclopentyl-1H-imidazo[4,5-c]quinolin-4-amine (41)
N-(3,4-Dichloro-phenyl)-2-cycloheptyl-1H-imidazo[4,5-c]quinolin-4-amine (42)
N-(3,4-Dichloro-phenyl)-2-furyl-1H-imidazo[4,5-c]quinolin-4-amine (43)
N-(3,4-Dichloro-phenyl)-2-cyclobutyl-1H-imidazo[4,5-c]quinolin-4-amine (44)
N-(3,4-Dichloro-phenyl)-2-cyclohexyl-1H-imidazo[4,5-c]quinolin-4-amine (45)
N-(3,4-Dichloro-phenyl)-2--1H-imidazo[4,5-c]quinolin-4-amine (46)
N-(3,4-Dichloro-phenyl)-2-pentyl-1H-imidazo[4,5-c]quinolin-4-amine (47).

These imidazoquinoline derivatives are also some preferred A₃RM in accordance with the invention. A specifically preferred imidazoquinoline derivative in accordance with the invention is N-(3,4-Dichloro-phenyl)-2-cyclohexyl-1H-imidazo[4,5-c]quinolin-4-amine (45)

BRIEF DESCRIPTION OF THE DRAWINGS

In order to understand the invention and to see how it may be carried out in practice, a preferred embodiment will now be described, by way of non-limiting example only, with reference to the accompanying drawings, in which:

Figure 1 is a scheme of the synthetic procedure of imidazoquinoline derivatives.

Figures 2A-2B are bar graphs showing the effect of imidazoquinoline derivative No. 45 on the number of white blood cells (WBC, **Figure 2A**) and neutrophils (**Figure 2B**) in naïve mice as compared to control;

Figure 3 is a graph showing the reduction in clinical score following treatment with imidazoquinoline derivative 45 a compared to the control.

DETAILED DESCRIPTION OF EXEMPLARY EMBODIMENTS

The present invention concerns allosteric modulation of the A₃ adenosine receptor (A₃AR) by the use of imidazoquinoline derivatives. It has been found that

- 8 -

imidazoquinoline derivatives may effectively increase the efficacy of the receptor, upon binding to thereto.

As appreciated, while the invention is described in the following detailed description with reference to therapeutic methods comprising treatment with allosteric modulators of A₃AR, it is to be understood that also encompassed within the present invention are pharmaceutical compositions comprising A₃ adenosine receptor allosteric modulators, the uses of such A₃ adenosine receptor allosteric modulators, as well as some novel imidazoquinoline derivatives found to be specifically effective as allosteric modulators of the receptor.

As used herein, the term "*allosteric modulation*" which may be used interchangeably with the term "*allosteric regulation*" denotes the regulation or modulation of an enzyme, receptor or other protein by binding of an effector molecule at the protein's allosteric site which is different from the binding site of the endogenous ligand.

Effectors that enhance the protein's activity are referred to as "*allosteric activators*" or "*allosteric enhancers*", whereas those that decrease the protein's activation are called "*allosteric inhibitors*".

Further, as used in the specification and claims, the forms "*a*", "*an*" and "*the*" include singular as well as plural references unless the context clearly dictates otherwise. For example, the term "*an imidazoquinoline derivative*" denotes one or more compounds being the same or different chemical modifications of imidazoquinoline.


Further, as used herein, the term "*comprising*" is intended to mean that the methods and compositions of the invention may include the recited imidazoquinoline derivative but not excluding other substances. The term "*consisting essentially of*" is used to define methods and compositions that include the recited components but exclude other components that may have an essential significance on the biochemical response resulting from the binding of imidazoquinoline derivative to the receptor. For example, a composition consisting essentially of an imidazoquinoline derivative as the active ingredient and a pharmaceutically acceptable carrier will not include or include only insignificant amounts (amounts that will have an insignificant effect on the activity of the receptor) of other compounds capable of binding to the allosteric site or binding site of the

- 9 -

receptor. "*Consisting of*" shall thus mean excluding more than trace elements of other components. Embodiments defined by each of these transition terms are within the scope of this invention.

Further, all numerical values, e.g. when referring the amounts or ranges of the components constituting the composition of the invention, are approximations which are varied (+) or (-) by up to 20%, at times by up to 10% of from the stated values. It is to be understood, even if not always explicitly stated that all numerical designations are preceded by the term "*about*".

Thus, in accordance with the first aspect, the present invention provides the use of an A₃ adenosine receptor allosteric modulator (A₃RM) for the preparation of a pharmaceutical composition for the preparation of a pharmaceutical composition for the treatment of a condition which requires for said treatment modulation of A₃ adenosine receptor (A₃AR), wherein said A₃RM has the following general formula (I):



Formula I

wherein:

- R₁ represents an aryl or alkaryl being optionally substituted at the aromatic ring once or more with a substituent selected C₁-C₁₀ alkyl, halo, C₁-C₁₀ alkanol, hydroxyl, C₁-C₁₀ acyl, C₁-C₁₀ alkoxy; C₁-C₁₀-alkoxycarbony, C₁-C₁₀ alkoxyalkyl; C₁-C₁₀ thioalkoxy; C₁-C₁₀ alkylether, amino, hydrazido, C₁-C₁₀ alkylamino, pyridylthio, C₂-C₁₀ alkenyl; C₂-C₁₀ alkynyl, thio, and C₁-C₁₀ alkylthio, acetoamido, sulfonic acid; or said substituents can form together a

- 10 -

cycloalkyl or cycloalkenyl fused to said aryl, the cycloalkyl or cycloalkenyl optionally comprising one or more heteroatoms; provided that said aryl is not an unsubstituted phenyl group;

- R_2 represents hydrogen or a substituent selected from C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl; C₂-C₁₀ alkynyl, C₄-C₁₀ cycloalkyl, C₄-C₁₀ cycloalkenyl or a five to seven membered heterocyclic aromatic ring, C₅-C₁₅ fused cycloalkyl, bicyclic aromatic or heteroaromatic rings; or C₁-C₁₀ alkylether, amino, hydrazido, C₁-C₁₀ alkylamino, C₁-C₁₀ alkoxy, C₁-C₁₀-alkoxycarbonyl, C₁-C₁₀ alkanol, C₁-C₁₀ acyl, C₁-C₁₀ thioalkoxy, pyridylthio, thio, and C₁-C₁₀ alkylthio, acetoamido, sulfonic acid.

and pharmaceutically acceptable salts thereof, for the preparation of a pharmaceutical composition for the treatment of a condition which requires for said treatment modulation of A₃ adenosine receptor (A₃AR).

Preferably, the composition is for enhancing A₃AR activity.

The term "*alkyl*" is used herein to refer to a linear or branched hydrocarbon chain having from 1 to 10 carbon atoms and more preferably 1 to 6 carbon atoms including, but not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n-heptyl, octyl and the like.

Similarly, the terms "*alkenyl*" and "*alkynyl*" denote a linear or branched hydrocarbon chain having, respectively, from 2 to 10, or from 3 to 10 carbon atoms and more preferably 2 to 6 or 3 to 6 carbon atoms, the alkenyl or alkynyl having at least one unsaturated bond.

The alkyl, alkenyl or alkynyl substituents may be substituted with a heteroatom containing group. Thus, it should be understood that while not explicitly stated, any of the alkyl modifications defined hereinabove and below, such as alkylthio, alkoxy, alkanol, alkylamine etc, also include the corresponding alkenyl or alkynyl modifications, such as, alkenylthio, alkenyloxy, alkenol, alkenylamine, or respectively, alkynylthio, alkynyloxy, alkynol, alkynylamine.

- 11 -

The term "**aryl**" denotes an unsaturated aromatic carbocyclic group of from 5 to 14 carbon atoms having a single ring (e. g., phenyl) or multiple condensed rings (e. g., naphthyl or anthryl). Preferred aryls include phenyl, indanyl, benzimidazole.

The term "**alkaryl**" refers to -alkylene-aryl groups preferably having from 1 to 10 carbon atoms in the alkylene moiety and from 6 to 14 carbon atoms in the aryl moiety. Such alkaryl groups are exemplified by benzyl, phenethyl and the like.

The term "**Substituted aryl**" refers to an aromatic moiety which is substituted with from 1 to 3 substituents as defined above. A variety of substituents are possible, as appreciated by those versed in the art. Nonetheless, some preferred substituents include, without being limited thereto, halogen, (substituted) amino, nitro, cyano, alkyl, alkoxy, acyloxy or alkanol, sulphonyl, sulphynyl.

The term "**Halo**" or "**halogen**" refers to fluoro, chloro, bromo and iodo, preferably to chloro.

The term "**acyl**" refers to the groups H-C(O)- as well as alkyl-C(O)-.

The term "**alkanol**" refers to the group -COH as well as alk-OH, "alk" denoting an alkylene, alkenylene or alkynylene chain.

The term "**alkoxy**" is used herein to mean -O-alkyl, including, but not limited to, methoxy, ethoxy, propoxy, isopropoxy, n-butoxy and the like.

The term "**alkylthio**" is used herein to mean -S-alkyl, including, but not limited to, methylthio, ethylthio, n-propylthio, isopropylthio, n-butylthio and the like.

The term "**alkoxyalkyl**" is used herein to mean -alkyl-O-alkyl, including, but not limited to, methoxymethyl, ethoxymethyl, n-propoxymethyl, isopropoxymethyl, n-butoxymethyl, isobutoxymethyl, t-butoxymethyl and the like.


The term "**cycloalkyl**" is used herein to mean cyclic hydrocarbon radicals including, but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and the like.

The term "**alkoxycarbonyl**" is used herein to mean -C(O)O-alkyl, including, but not limited to, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl and the like.

- 12 -

The term "*fused cycloalkyl*" is used herein to mean any compound or substituent comprising at least two aliphatic rings which are connected at a single atom (to form a spirocyclic moiety), at two mutually bonded atoms or across a sequence of atoms (bridgehead). The fused rings may include any bicyclic, tricyclic as well as polycyclic moieties. Bicyclic substituents are preferred in accordance with this embodiment of the invention.


According to a more specific and preferred embodiment of the invention, the R_1 substituent in A_3RM has the following general formula (II):




wherein n is 0 or an integer selected from 1-5; preferably, n is 0, 1 or 2; and

- X_1 and X_2 which may be the same or different, are selected from hydrogen halogen, alkyl, alcohol or alkoxy, indanyl, pyrroline provided that when said n is 0, X_1 and X_2 are not hydrogen.

In yet a further preferred embodiment, R_1 in said A_3RM is a substituent having the above formula (II), wherein X_1 or X_2 , which may be the same or different, are selected from hydrogen, chloro, methoxy, methanol or a substituent having the formulae (IIIa) or (IIIb):



(IIIa)



(IIIb)


wherein Y is selected from N or CH.

In further embodiment R_2 in said A_3RM is selected from H, C_{1-10} alkyl, C_{4-10} cycloalkyl, the alkyl chain may be a straight or branched or form a four to seven membered cycloalkyl ring.

- 13 -

In yet a further embodiment, R_2 in said A_3RM is selected from a five to seven membered heterocyclic aromatic ring.

More preferred R_2 substituents are selected from H, n-pentyl, or a five membered heterocyclic aromatic ring having the following formula (IV):



(IV)

wherein Z is selected from O, S or NH, preferably O.

In accordance with another embodiment of the invention R_2 comprises fused rings, particularly so as to form bicyclic substituents. Non-limiting examples of bicyclic compounds which may be used to form the substituents in the context of the invention comprise bicyclo[2.2.1]heptane, bicyclo[4.1.0]heptane, bicyclo[4.1.0]heptan-3-carboxylic acid, bicyclo[3.1.0]hexan-3-carboxylic acid, bicyclo[4.1.0]heptan-2-carboxylic acid, bicyclo[3.1.0]hexan-2-carboxylic acid, and bicyclo[2.2.1]heptan-2-carboxylic acid.

In accordance with yet another embodiment, R_2 may be selected from 2-cyclohexene and 3-cyclohexene.

Specific imidazoquinoline derivatives in accordance with the invention are listed below:

- N-(4-Methyl-phenyl)-2-cyclopentyl-1H-imidazo[4,5-c]quinolin-4-amine (31)
- N-(4-Methoxy-phenyl)-2-cyclopentyl-1H-imidazo[4,5-c]quinolin-4-amine (32)
- N-(3,4-Dichloro-phenyl)-2-cyclopentyl-1H-imidazo[4,5-c]quinolin-4-amine (33)
- N-(4-Chloro-phenyl)-2-cyclopentyl-1H-imidazo[4,5-c]quinolin-4-amine (34)
- N-(3-Methanol-phenyl)-2-cyclopentyl-1H-imidazo[4,5-c]quinolin-4-amine (35)
- N-([3,4-c]Indan)-2-cyclopentyl-1H-imidazo[4,5-c]quinolin-4-amine (36)
- N-(1H-indazol-6-yl)-2-cyclopentyl-1H-imidazo[4,5-c]quinolin-4-amine (37)
- N-(4-Methoxy-benzyl)-2-cyclopentyl-1H-imidazo[4,5-c]quinolin-4-amine (38)
- N-(1H-Indol-6-yl)-2-cyclopentyl-1H-imidazo[4,5-c]quinolin-4-amine (39)
- N-(Benzyl)-2-cyclopentyl-1H-imidazo[4,5-c]quinolin-4-amine (40)
- N-(Phenylethyl)-2-cyclopentyl-1H-imidazo[4,5-c]quinolin-4-amine (41)

- 14 -

N-(3,4-Dichloro-phenyl)-2-cycloheptyl-1H-imidazo[4,5-c]quinolin-4-amine (42)

N-(3,4-Dichloro-phenyl)-2-furyl-1H-imidazo[4,5-c]quinolin-4-amine (43)

N-(3,4-Dichloro-phenyl)-2-cyclobutyl-1H-imidazo[4,5-c]quinolin-4-amine (44)

N-(3,4-Dichloro-phenyl)-2-cyclohexyl-1H-imidazo[4,5-c]quinolin-4-amine (45)

N-(3,4-Dichloro-phenyl)-2--1H-imidazo[4,5-c]quinolin-4-amine (46)

N-(3,4-Dichloro-phenyl)-2-pentyl-1H-imidazo[4,5-c]quinolin-4-amine (47).

In general, the novel derivatives 31 - 47 were synthesized as shown in the scheme depicted in Fig 1. Condensation of anthranilic acid hydrochloride (1) with methazonic acid (2) resulted in 2- β -nitroethylideneaminobenzoic acid (3), which was dehydrated in acetic anhydride in the presence of potassium acetate to give 3-nitro-4-hydroxyquinoline (5) [Bachman, G. B. et al. Quinoline Derivatives from 3-Nitro-4-hydroxyquinoline, *J. Am. Chem. Soc.*, 1947, 69, 365-371]. 3-Nitro-4-hydroxyquinoline (5) was treated with phosphorous oxychloride to afford 3-nitro-4-chloroquinoline (6). This was converted to 3-nitro-4-aminoquinoline (7) with ammonia, which was subsequently reduced by catalytic hydrogenation to 3,4-diaminoquinoline (8) with 10 % palladium on charcoal as catalyst. The next step involved ring-closure, which was carried out in three different ways. For example, Compound 10 was prepared by ring closure of the appropriate carboxylic acid and 3,4-diaminoquinoline (8) in polyphosphoric acid [Young, R. C. et al. Purine Derivatives as Competitive Inhibitors of Human Erythrocyte Membrane Phosphatidylinositol 4-Kinase. *J. Med. Chem.* 1990, 33, 2073-2080]. Compound 14 was prepared by ring-closure of 2-furoyl chloride with 3,4-diaminoquinoline (8) [Scammells P.J. et al. Substituted 1,3-dipropylxanthines as irreversible antagonists of A1 adenosine receptors. *J. Med. Chem.* 1994, 37, 2704-2712]. Compound 9 was prepared by ring-closure of 3,4-diaminoquinoline (8) with formic acid in trimethylorthoformate. Oxidation with 3-chloroperoxybenzoic acid afforded 5-oxides 16-22, which subsequently could be converted with phosphorous oxychloride into the 4-chlorides 23-29. Finally, reaction with the appropriate amines afforded the desired compounds 30-47, respectively [Van Galen, P. J. M. et. al. 1-*H*-imidazo[4,5-*c*]quinolin-4-amines: Novel Non-Xanthine Adenosine Antagonists. *J. Med. Chem.* 1991, 34, 1202-1206].

It was surprisingly found that modifying the Van Galen procedure by using microwave irradiation (a short period of about 40 min. max) in the last reaction step

- 15 -

resulted in a significant reduction in the required reaction time as well as an easier and more straightforward purification of the end products. This was unexpected since microwave irradiation has not been thought to be relevant for this particular reaction.

It is noted that the above specific imidazoquinoline derivatives are novel *per se* and all have been shown to modulate the response obtained by their allosteric binding to A₃AR.

The imidazoquinoline derivatives of the invention were shown to have, on the one hand, reduced affinity, if any, to the orthosteric binding sites of the A₁ and A_{2A}, A_{2B} adenosine receptors and reduced affinity to the orthosteric binding site of the A₃ adenosine receptor, and on the other hand, high affinity to the allosteric site of the A₃ adenosine receptor. This finding was unexpected in light of the non-specific affinity of known imidazoquinoline derivatives, such as *N*-phenyl-2-cyclopentyl-1*H*-imidazo[4,5-*c*]quinolin-4-amine (compound 30) to the orthosteric as well as allosteric binding sites of these receptors. The selective affinity of the derivatives disclosed herein is particularly evident with respect to compounds 33, 42, 44 and 45 in Tables 1 and 2.

As further shown in **Table 2** hereinafter, the specific imidazoquinoline derivatives of the invention were shown to increase the activity of the A₃AR. Thus, in accordance with a further preferred embodiment of the invention modulation comprises enhancement of A₃AR activity. In this context, the A₃AM are considered as A₃AR activators.

The term "**enhancement**" denotes the effect of the imidazoquinoline derivative on the receptor exhibited by an increase of at least 15% in the efficacy of the A₃ adenosine receptor by binding of the imidazoquinoline to the allosteric site of the receptor and/or by a decrease in dissociation rate of adenosine or an A₃AR agonist to the orthosteric binding site.

Thus, in accordance with another of its aspects, the present invention provides a method of modulating A₃ adenosine receptor (A₃AR) in a subject, the method comprises administering to said subject an amount of an A₃ adenosine receptor allosteric modulator (A₃RM), the amount being effective to modulate A₃AR, wherein said A₃RM has the general formula (I) as defined above.

- 16 -

The invention also provides a method of treating a subject for a condition which requires for said treatment modulation of A₃ adenosine receptor (A₃AR), the method comprises administering to said subject an amount of the A₃RM as defined above, the amount being effective to modulate A₃AR activity.

The term treatment "*treatment*" as used herein refers to the administering of a therapeutic amount of the imidazoquinoline derivative as defined herein, alone or in combination with a ligand to the A₃AR orthosteric binding site which is effective to achieve a therapeutic effect, the therapeutic effect being selected from one or more of the following: amelioration of undesired symptoms associated with a disease, prevention of the manifestation of such symptoms before they occur, slowing down a progression of the disease, slowing down any deterioration of symptoms, enhancement of onset of a remission period, slowing down of any irreversible damage caused in a progressive chronic stage of the disease, delaying of the onset of said progressive stage, lessening of the severity or cure of a disease, improving survival rate or more rapid recovery from a disease, preventing the disease from occurring or a combination of two or more of the above.

A variety of conditions may be treated by the modulation of the A₃AR depending on the specific effect the imidazoquinoline has on the receptor.

When said modulation comprises inhibition of or decrease in efficacy of the receptor, the condition may be any condition which may also be treated by the binding of an A₃ adenosine receptor antagonist. Such conditions comprise, without being limited thereto, certain malignancies, certain immuno-compromised afflictions, and high intraocular pressure.

When said modulation comprises enhancement or increase in efficacy of the receptor, the condition may be any condition which may also be treated by the binding of an A₃ adenosine receptor agonist. Such conditions comprise, without being limited thereto, hyperproliferative disorders, and in particular all types of solid tumors; skin proliferative diseases (e.g. psoriasis); a variety of benign hyperplastic disorders; inflammatory diseases; ischemic conditions, such as myocardial or renal ischemia.

The term "*solid tumors*" refers to carcinomas, sarcomas, adenomas, and cancers of neuronal origin and in fact to any type of cancer which does not originate from the

- 17 -

hematopoietic cells and in particular concerns: carcinoma, sarcoma, adenoma, hepatocellular carcinoma, hepatocellular carcinoma, hepatoblastoma, rhabdomyosarcoma, esophageal carcinoma, thyroid carcinoma, ganglioblastoma, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, synovioama, Ewing's tumor, leiomyosarcoma, rhabdotheliosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, renal cell carcinoma, hematoma, bile duct carcinoma, melanoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, testicular tumor, lung carcinoma, small lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocyoma, medulloblastoma, craniopharyngioma, ependynoma, pinealoma, retinoblastoma, multiple myeloma, rectal carcinoma, thyroid cancer, head and neck cancer, brain cancer, cancer of the peripheral nervous system, cancer of the central nervous system, neuroblastoma, cancer of the endometrium, as well as metastasis of all the above. It has been shown in accordance with the invention that increased expression of A₃AR can be found not only in the primary tumor site but also in metastases thereof.

Benign hyperplastic disorders include, without being limited thereto, benign prostate hyperplasia (BPH), non-tumorigenic polyps in the digestive tract, in the uterus and others.

Inflammatory diseases include, without being limited thereto, rheumatoid arthritis, Crohn's disease, multiple sclerosis and others.

It should be appreciated that the method of the invention may also comprise the combined administration of the A₃RM in combination with a ligand to the orthosteric binding site. When modulation involves enhancement of the receptor, the A₃RM may be administered in combination with adenosine or an A₃AR agonist.

The term "*combination*" includes a schedule of treatment that involves administration of at least the A₃RM and the ligand to the orthosteric site. The schedule of treatment may comprise simultaneous or co-administration of the two active principles, or with an interval between administrations.

According to a preferred embodiment, the A₃RM is administered to the subject orally, although other administration routes are applicable, including parenteral

- 18 -

(intravenous, intramuscular, intra-arterial, subcutaneous, intranasal, via the lungs (inhalation)).

The A₃RM is preferably used and administered in combination with a physiologically acceptable carrier to form a pharmaceutical composition, the latter also forming part of the invention.

The term "*physiologically acceptable excipient*" denotes any excipient that is useful in preparing a pharmaceutical composition or formulation that is generally safe, non-toxic and neither biologically nor otherwise undesirable, and includes a excipient that is acceptable for veterinary use as well as human pharmaceutical use.

In making the compositions of this invention, the imidazoquinoline derivative is usually mixed with the excipient, diluted by an excipient or enclosed within a carrier which can be in the form of a capsule, sachet, paper or other container. When the excipient serves as a diluent, it can be a solid, semi-solid, or liquid material, which acts as a vehicle, carrier or medium for the imidazoquinoline derivative. Thus, the compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), soft and hard gelatin capsules, suppositories, sterile injectable solutions, and sterile packaged powders.

The effective amount of imidazoquinoline derivative in the pharmaceutical composition and unit dosage form thereof may be varied or adjusted widely depending upon the particular application, the manner of introduction, the potency of the particular compound, and the desired concentration. The effective amount is typically determined in appropriately designed clinical trials (dose range studies) and the person versed in the art will know how to properly conduct such trials in order to determine the effective amount. As generally known, an effective amount depends on a variety of factors including the affinity of the imidazoquinoline derivative to the allosteric binding site, its distribution profile within the body, a variety of pharmacological parameters such as half life in the body, on undesired side effects, if any, on factors such as age and gender, etc.

The term "*unit dosage forms*" refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in

- 19 -

association with a suitable pharmaceutical excipient. The amount of therapeutically active compound in such a unit dosage form may vary from about 0.5 mg to 500 mg.

In this case, the composition of the invention will typically be administered over an extended period of time in a single daily dose, in several doses a day, as a single dose and in several days, etc. The treatment period will generally have a length proportional to the length of the disease process and the specific imidazoquinoline derivative effectiveness and the patient species being treated.

SOME EXEMPLARY EMBODIMENTS

Materials and Methods

Instruments and Analysis

Microwave-assisted chemistry was performed on an Emrys™ Optimizer with Emrys™ Optimizer software. For the reactions round-bottom vials with a volume of 2-5 mL were used.

¹H-NMR spectra were measured at 200 MHz with a Bruker AC 200 or Bruker DMX 600 spectrometer. ¹³C-NMR spectra were measured at 50 or 150 MHz. Chemical shifts for ¹H and ¹³C are given in ppm (δ) relative to tetramethylsilane (TMS) as internal standard, coupling constants are given in Hz. Melting points were determined with a Büchi capillary melting point apparatus and are uncorrected. Combustion analyses of new target compounds were performed by the analytical department of the Gorlaeus Laboratories, Leiden University (The Netherlands) and are within 0.4 % of theoretical values unless otherwise specified.

Chemical Synthesis

2-β-Nitroethylideaminobenzoic acid (compound 3)

Compound 3 was prepared as described elsewhere [Bachman, G. B. et al. Quinoline Derivatives from 3-Nitro-4-hydroxyquinoline, *J. Am. Chem. Soc.*, **1947**, *69*, 365-371]. In brief, a solution of NaOH (13.4 g) in water (26.8 ml) was cooled and stirred. Nitromethane (6.7 g, 5.9 ml, 110 mmol) was added dropwise, keeping the temperature at 25-30 °C. The mixture was then warmed to 40 °C and again cooled and stirred while another portion of nitromethane (6.7 g, 5.9 ml, 110 mmol) was added

- 20 -

slowly at 40-45 °C. This temperature was maintained until all solid was dissolved and a clear red solution was obtained. The solution was then heated to 50-55 °C for two to five minutes and finally cooled to 30 °C, poured on chipped ice (30 g) and acidified with concentrated HCl (30 ml). The resultant solution of methazonic acid **2** was immediately added to a solution of anthranilic acid **1** (13.7 g, 100 mmol) and concentrated HCl (9.2 ml) in water (200 ml). Yellow precipitate formed, which was left to stand at room temperature for 12-18 h. The precipitate was filtered off and washed with water. The cake was sliced into thin flakes and dried. Yield: 18.40 g (89%). Mp.: 196°-197 °C. ¹H NMR (DMSO-*d*₆): δ 6.76 (d, 2H, *J* = 6.6 Hz, CH₂); 7.24 (t, 1H, *J* = 6.6 Hz, N=CH); 7.54-7.82 (m, 2H, Ar); 8.02-8.12 (m, 2H, Ar); 12.09 (s, 1H, COOH).

3-Nitro-4-hydroxyquinoline (compound 5)

Compound **5** was prepared as described elsewhere [Bachman, G. B. et al. Quinoline Derivatives from 3-Nitro-4-hydroxyquinoline, *J. Am. Chem. Soc.*, **1947**, *69*, 365-371]. In brief, a mixture of 2-β-nitroethylideneaminobenzoic acid **3** (10.4 g, 50 mmol) and technical acetic anhydride (50 ml) was placed in a 3-necked flask of at least 100 mL capacity fitted with thermometer, magnetic stirrer and reflux condenser. It was stirred and heated to 100-105 °C until a clear solution was obtained. Heating was then discontinued and anhydrous potassium acetate (5.0 g, 51 mmol) was added rapidly with stirring. The temperature rose spontaneously to 134-138 °C. When it began to fall (five to ten minutes) external heating was applied and the mixture was refluxed for fifteen minutes with vigorous stirring, then allowed to cool slowly to room temperature. The product filtered off and washed with glacial acetic acid until the washings were colorless. Then suspended in water (50 ml) and dried in vacuum at 80 °C. Yield: 6.93 g (49%). Mp.: >300 °C. ¹H NMR (DMSO-*d*₆): δ 7.54 (t, 1H, *J* = 7.3 Hz, Ar); 7.76-7.86 (m, 2H, Ar); 8.27 (d, 1H, *J* = 8.0 Hz, Ar); 9.21 (s, 1H, Ar).

3-Nitro-4-chloroquinoline (compound 6)

Compound **6** was prepared as described elsewhere [Van Galen, P. J. M. et. al. 1-*H*-imidazo[4,5-*c*]quinolin-4-amines: Novel Non-Xanthine Adenosine Antagonists. *J. Med. Chem.* **1991**, *34*, 1202-1206]. In brief, 3-Nitro-4-hydroxyquinoline **5** (5.7 g, 30 mmol) was added to phosphorus oxychloride (70.0 g, 41.2 ml, 450 mmol) with stirring.

- 21 -

The mixture was refluxed for 30 minutes. After cooling the solvent was poured over crushed ice while stirring. After 1 hour the solid that was formed was filtered off, washed with cold water and dissolved in ethyl acetate. The solution was extracted with ice-cold NaOH (1 M) till pH= 8-9 and dried over MgSO₄. The solvent was evaporated and the residue was dried. Yield: 5.05 g (81%). Mp.: 118°-119 °C. ¹H NMR (DMSO-*d*₆): δ 7.94-8.11 (m, 2H, Ar); 8.25 (d, 1H, *J* = 8.0 Hz, Ar); 8.47 (d, 1H, *J* = 9.5 Hz, Ar); 9.42 (s, 1H, Ar).

3-Nitro-4-aminoquinoline (compound 7)

Compound 7 was prepared as described elsewhere [Van Galen, P. J. M. et. al. (1991) *ibid.*]. In brief, ammonia gas was passed, while stirring, through a solution of 3-nitro-4-chloroquinoline 6 (7.0 g, 30 mmol) in toluene (95 ml) and propanol (15 ml) till the product was formed. During the course of the reaction, the temperature was gradually raised till 70 °C. After cooling, the solid was separated by filtration and washed successfully with toluene/2-propanol (70:30), ether and cold water until Cl⁻ could no longer be detected. The solid was filtered off and dried at 80 °C. Yield: 6.1 g (95%). Mp.: 255-257 °C. ¹H NMR (DMSO-*d*₆): δ 7.50-7.66 (m, 1H, Ar); 7.81-7.92 (m, 2H, Ar); 8.59 (d, 1H, *J* = 8.0 Hz, Ar); 9.03 (broad s, 2H, NH₂); 9.18 (s, 1H, Ar)

3,4-Diaminoquinoline (compound 8)

Compound 8 was prepared as described elsewhere [Van Galen, P. J. M. et. al. (1991) *ibid.*]. In brief, to a mixture of 3-nitro-4-aminoquinoline 7 (3.2 g, 20 mmol) in absolute ethanol (60 ml) was added 10% palladium on charcoal (0.17 g). The mixture was hydrogenated under 2.5-3.5 atm pressure till the product was formed and subsequently filtered over Hyflo. The filtrate was evaporated and the residue was gradually solidified and dried in vacuum. Yield: 2.66 g (98%). Mp.: 183-185 °C. MS (ESI) *m/z* 161.0 (M + 1)⁺. ¹H NMR (DMSO-*d*₆): δ 4.73 (broad s, 2H, NH₂); 5.88 (s, 2H, NH₂); 7.16-7.37 (m, 2H, Ar); 7.64-7.70 (m, 1H, Ar); 7.98-8.03 (m, 1H, Ar); 8.22 (s, 1H, Ar).

General procedure of 1*H*-Imidazo[4,5-*c*]quinolines (Compounds 9-13)

1*H*-Imidazo[4,5-*c*]quinolines were prepared as described elsewhere [Young, R. C. et al. Purine Derivatives as Competitive Inhibitors of Human Erythrocyte Membrane

- 22 -

Phosphatidylinositol 4-Kinase. *J. Med. Chem.* 1990, 33, 2073-2080]. In brief, polyphosphoric acid (1.3 ml/mmol) was added to 3,4-diaminoquinoline **8** and the appropriate carboxylic acid (1.2 eq.). The mixture was stirred at 100 °C for 5 hours. Then cooled to 0 °C and NH₄OH was added slowly till pH = 8-9. The mixture was extracted with ethyl acetate (3 times 15 ml), then washed with water, brine and again water and dried over MgSO₄. The solvent was evaporated and the residue was dried.

1*H*-Imidazo[4,5-*c*]quinoline (compound 9)

Compound **9** was prepared as described elsewhere [Van Galen, P. J. M. et. al. (1991) *ibid.*]. In brief, compound **8** (1.4g, 8.71 mmol) was heated under stirring with trimethyl orthoformate (23.8 ml). To a clear solution was cautiously added formic acid (0.45 ml) whereupon solid precipitated. The mixture was refluxed for 1 hour. After cooling to 40 °C, ether (3.1 ml) and absolute ethanol (0.36 ml) were added and the mixture was cooled on ice for 1 hour. The solid that was formed was filtered off, washed with ether and subsequently with ethyl acetate and dried. Yield: 0.44 g (81%). Mp.: 263-265 °C. ¹H NMR (DMSO-*d*₆): δ 7.67-7.72 (m, 2H, Ar); 8.18 (s, 1H, Ar); 8.29-8.34 (m, 1H, Ar); 8.61-8.65 (m, 1H, Ar); 8.93 (s, 1H, Ar).

2-Cyclobutyl-1*H*-Imidazo[4,5-*c*]quinoline (compound 10)

Scale: 6.2 mmol. Eluent for column chromatography was ethyl acetate:petroleum ether = 1:1. Yield: 0.88 g (63%). Mp.: 191-192 °C. MS (ESI) *m/z* 223.6 (M + 1)⁺. ¹H NMR (CD₃OD): δ 1.95-2.32 (m, 2H, CH₂); 2.44-2.66 (m, 4H, 2 CH₂); 3.82-4.01 (m, 1H, CH); 7.58-7.71 (m, 2H, Ar); 8.01-8.11 (m, 1H, Ar); 8.32-8.38 (m, 1H, Ar); 9.01 (s, 1H, Ar).

2-Cyclopentyl-1*H*-Imidazo[4,5-*c*]quinoline (compound 11).

Scale: 4.0 mmol. Eluent for column chromatography was 5% methanol in dichloromethane. Yield: 0.77 g (81%). Mp.: 192 °C. ¹H NMR (CDCl₃): δ 1.70-1.88 (m, 6H, 3 CH₂); 2.03-2.22 (m, 2H, CH₂); 3.39-3.56 (m, 1H, CH); 7.27 (s, 1H, Ar); 7.53-7.66 (m, 2H, Ar); 8.21 (d, 2H, *J* = 8.0 Hz, Ar); 9.18 (s, 1H, NH).

- 23 -

2-Cyclohexyl-1H-Imidazo[4,5-c]quinoline (compound 12).

Scale: 6.3 mmol. Eluent for column chromatography was 1-5% methanol in dichloromethane. Yield: 0.60 g (38%). Mp.: 205-206°C. MS (ESI) m/z 251.7 ($M + 1$)⁺. ¹H NMR (CDCl₃): δ 1.12-1.39 (m, 4H, 2 CH₂); 1.66-1.77 (m, 4H, 2 CH₂); 2.16-2.21 (m, 2H, CH₂); 3.01-3.13 (m, 1H, CH); 7.41-7.60 (m, 2H, Ar); 8.19 (d, 1H, $J = 8.8$ Hz, Ar); 8.31 (d, 1H, $J = 8.0$ Hz, Ar); 9.16 (s, 1H, Ar).

2-Cycloheptyl-1H-Imidazo[4,5-c]quinoline (compound 13).

Scale: 6.3 mmol. Eluent for column chromatography was 1-5% methanol in dichloromethane. Yield: 0.45 g (27%). Mp.: 225-226 °C. MS (ESI) m/z 266.3 ($M + 1$)⁺. ¹H NMR (CDCl₃): δ 1.25-1.24 (m, 12H, 6 CH₂); 3.20-3.32 (m, 1H, CH); 7.42-7.62 (m, 2H, Ar); 8.20 (d, 1H, $J = 8.0$ Hz, Ar); 8.33 (d, 1H, $J = 8.0$ Hz, Ar); 9.19 (s, 1H, Ar).

2-Furyl-1H-Imidazo[4,5-c]quinoline (compound 14)

2-Furoyl chloride (1.1 g, 0.8 ml, 8.1 mmol) in dry dichloromethane (15 ml) was added dropwise to a solution of 3,4-diaminoquinoline 8 (1.0 g, 6.0 mmol) in dry pyridine (6.2 ml) under nitrogen. The solution was stirred for 2 hours at room temperature. Water (15 ml) was added to quench the reaction and the solvent was evaporated under reduced pressure to afford an orange solid. This crude solid in 2N NaOH (15 ml) was refluxed for 2 hours. After cooling on ice the pH was adjusted to 7 using concentrated HCl. The solid that precipitated was filtered off and washed with water and ether. Then extracted with ethyl acetate (3 times 15 ml) and washed with water (3 times 15 ml) and dried over MgSO₄. The solvent was evaporated and the residue was dried. Eluent for column chromatography was 1-5% methanol in dichloromethane. Yield: 0.62 g (44%). Mp.: 236-238 °C. ¹H NMR (DMSO-*d*₆): δ 6.74 (s, 1H, Ar); 7.35 (d, 1H, $J = 3.7$ Hz, Ar); 7.69-7.73 (m, 2H, Ar); 7.83 (s, 1H, Ar); 8.09 (s, 1H, Ar); 8.46 (s, 1H, Ar); 9.09 (s, 1H, Ar). ¹³C NMR (DMSO-*d*₆): δ 111.4, 112.6, 120.7, 121.8, 126.5, 127.2, 129.5, 138.2, 143.6, 144.3, 145.1, 147.2, 155.4.

2-Pentyl-1H-Imidazo[4,5-c]quinoline (compound 15).

Prepared as described for the furyl compound (14) using hexanoyl chloride (1.75 g, 13 mmol). Eluent for column chromatography was ethyl acetate:petroleum ether 1:4

- 24 -

to 4:1. Yield: 0.85 g (41%); mp 142-143 °C. ¹H NMR (DMSO-*d*₆): δ 0.91 (t, 3H, *J* = 6, CH₃), 1.37-1.39 (m, 4H, 2 x CH₂), 1.83-1.91 (m, 2H, CH₂), 1.93-2.30 (t, 2H, *J* = 8, CH₂), 7.64-7.69 (m, 2H, Ar); 8.08-8.13 (m, 1H, Ar); 8.28-8.42 (m, 1H, Ar); 9.12 (s, 1H, Ar).

General procedure of 2-substituted 1*H*-Imidazo[4,5-*c*]quinolin-5-oxide (compounds 16-22)

Starting material (9-15) was almost completely dissolved (with heating) in chloroform (2.5 ml/mmol), dichloromethane (2.5 ml/mmol) and methanol (0.25 ml/mmol). 3-Chloroperoxybenzoic acid (2.5 eq.) was added and the solution was reflux. After 30 minutes Na₂CO₃ (0.04 g/mmol) was added and the mixture was refluxed for one more hour. The reaction mixture was cooled on an ice-bath and the solvent was evaporated. Column chromatography was needed for purification and removal of 3-chloroperoxybenzoic acid.

1*H*-Imidazo[4,5-*c*]quinolin-5-oxide (compound 16)

Scale: 8.3 mmol. Eluent for column chromatography was 2% methanol in dichloromethane. Yield: 0.55 g (36%). Mp.: 290-295 °C. ¹H NMR (CD₃OD): δ 7.41-7.61 (m, 1H, Ar); 7.87-7.96 (m, 2H, Ar); 8.45-8.53 (m, 1H, Ar); 8.75-8.80 (m, 1H, Ar); 9.16 (s, 1H, Ar).

2-Cyclobutyl-1*H*-imidazo[4,5-*c*]quinolin-5-oxide (compound 17).

Scale: 1.8 mmol. Eluent for column chromatography was 2% (increased to 6%) methanol in dichloromethane. Yield: 0.18 g (42%). Mp.: 123-130 °C. ¹H NMR (DMSO-*d*₆): δ 1.95-2.22 (m, 2H, CH₂); 2.38-2.59 (m, 4H, 2 CH₂); 3.41-3.93 (m, 1H, CH); 7.72-7.93 (m, 2H, Ar); 8.39-8.41 (m, 1H, Ar); 8.65-8.99 (m, 1H, Ar); 11.52 (s, 1H, Ar).

2-Cyclopentyl-1*H*-imidazo[4,5-*c*]quinolin-5-oxide (compound 18).

Scale: 0.8 mmol. Eluent for column chromatography was 5% methanol in dichloromethane. Yield: 0.19 g (95%). Mp.: 155-157 °C. ¹H NMR (CD₃OD): δ 1.74-2.13 (m, 6H, 3 CH₂); 2.18-2.39 (m, 2H, CH₂); 3.38-3.54 (m, 1H, CH); 7.29-7.42 (m, 2H, Ar); 7.83-7.92 (m, 2H, Ar); 9.03 (s, 1H, Ar).

- 25 -

2-Cyclohexyl-1*H*-imidazo[4,5-*c*]quinolin-5-oxide (compound 19).

Scale: 2.4 mmol. Eluent for column chromatography was 5-10% methanol in dichloromethane. Yield: 0.59 g (92%). Mp.: 160-165 °C. ¹H NMR (CD₃OD): δ 1.17-2.19 (m, 10H, 5 CH₂); 2.97-3.12 (m, 1H, CH); 7.79-7.93 (m, 2H, Ar); 8.42-8.46 (m, 1H, Ar); 8.69-8.77 (m, 1H, Ar); 9.03 (s, 1H, Ar). ¹³C NMR (CD₃OD): δ 26.6, 26.8, 32.5, 39.7, 120.8, 123.1, 128.6, 129.9, 130.1, 130.3, 132.5, 138.0, 142.6, 164.1, 166.0, 170.9, 173.8.

2-Cycloheptyl-1*H*-imidazo[4,5-*c*]quinolin-5-oxide (compound 20).

Scale: 2.0 mmol. Eluent for column chromatography was 3-8% methanol in dichloromethane. Yield: 0.22 g (39%). Mp.: 115-120 °C. ¹H NMR (CD₃OD): δ 1.67-2.11 (m, 12H, 6 CH₂); 3.05-3.31 (m, 1H, CH); 7.78-7.90 (m, 2H, Ar); 8.28-8.48 (m, 1H, Ar); 8.62-8.73 (m, 1H, Ar); 9.00 (s, 1H, Ar). ¹³C NMR (CD₃OD): δ 25.0, 26.4, 32.1, 39.2, 117.4, 118.2, 120.6, 126.2, 127.4, 127.8, 128.2, 130.0, 130.6, 132.3, 132.6, 135.2, 162.7, 166.5.

2-Furyl-1*H*-imidazo[4,5-*c*]quinolin-5-oxide (compound 21).

Scale: 2.2 mmol. Eluent for column chromatography was 1-10% methanol in dichloromethane. Yield: 0.36 g (66%). Mp.: >280 °C. ¹H NMR (CD₃OD): δ 6.74-6.77 (m, 1H, Ar); 7.37-7.47 (m, 2H, Ar); 7.87-7.96 (m, 2H, Ar); 8.55-8.60 (m, 1H, Ar); 8.74-8.79 (m, 1H, Ar); 9.07 (s, 1H, Ar).

2-Pentyl-1*H*-imidazo[4,5-*c*]quinolin-5-oxide (compound 22).

Scale: 3.34 mmol. Eluent for column chromatography was 1-5% methanol in dichloromethane. Yield: 0.12 g (14%): ¹H NMR (CD₃OD): δ 0.88-0.94 (t, 3H, CH₃, *J* = 6 Hz); 1.26-1.39 (m, 4H, 2 x CH₂); 1.81-1.88 (m, 2H, CH₂), 2.88-2.95 (t, 2H, CH₂, *J* = 8 Hz); 7.44-7.58 (m, 2H, Ar); 7.90-8.09 (m, 2H, Ar); 9.03 (s, 1H, Ar).

General procedure of 4-chloro-1*H*-imidazo[4,5-*c*]quinoline (compounds 23-29)

A mixture of toluene (0.45 ml/mmol) and dimethylformamide (0.90 ml/mmol) was cooled in an ice-bath and phosphorus oxychloride (2.6 eq.) was added. After 10 minutes the appropriate 1*H*-imidazo[4,5-*c*]quinolin-5-oxide was added and the solution

- 26 -

was stirred at room temperature for 10 minutes. Subsequently the solution was heated to 100 °C on a steam bath for 30 minutes. Upon cooling, the solvent was evaporated and the resulting syrup was poured over crushed ice while stirring. The mixture was then warmed to room temperature and carefully adjusted to pH 6-7 with solid NaHCO₃. After 2 hours, the solid that was formed was filtered off, washed with water and diisopropylether and subsequently dried.

4-Chloro-1*H*-imidazo[4,5-*c*]quinoline (compound 23)

Scale: 3.5 mmol. Eluent for column chromatography was 2% methanol in dichloromethane. Yield: 0.31 g (44%). Mp.: 257-258 °C. MS (ESI) *m/z* 203.8 (M + 1)⁺, 206.0 (M + 3)⁺. ¹H NMR (CDCl₃): δ 8.46-8.56 (m, 2H, Ar); 8.82-8.87 (m, 1H, Ar); 9.14-9.19 (m, 1H, Ar); 9.35 (s, 1H, Ar); 10.16 (broad s, 1H, NH).

4-Chloro-2-cyclobutyl-1*H*-imidazo[4,5-*c*]quinoline (compound 24).

Scale: 0.6 mmol. Yield: 0.16 g (99%). Mp.: 142-145 °C. ¹H NMR (CDCl₃): δ 2.06-2.24 (m, 2H, CH₂); 2.52-2.66 (m, 4H, 2 CH₂); 3.87-4.00 (m, 1H, CH); 7.56-7.68 (m, 2H, Ar); 8.02-8.06 (m, 1H, Ar); 8.30-8.32 (m, 1H, Ar).

4-Chloro-2-cyclopentyl-1*H*-imidazo[4,5-*c*]quinoline (compound 25).

Scale: 12.7 mmol. Yield: 2.65 g (75%). Mp.: > 265 °C. ¹H NMR (CD₃OD): δ 1.81-2.22 (m, 6H, 3 CH₂); 2.25-2.31 (m, 2H, CH₂); 3.40-3.51 (m, 1H, CH); 7.63-7.74 (m, 2H, Ar); 8.00-8.03 (m, 1H, Ar); 8.33-8.38 (m, 1H, Ar).

4-Chloro-2-cyclohexyl-1*H*-imidazo[4,5-*c*]quinoline (compound 26).

Scale: 2.2 mmol. Yield: 0.65 g (97%). Mp.: 245-250 °C. MS (ESI) *m/z* 285.9 (M + 1)⁺, 288.0 (M + 3)⁺. ¹H NMR (CD₃OD): δ 1.37-2.17 (m, 10H, 5 CH₂); 3.03-3.18 (m, 1H, CH); 7.68-7.71 (m, 2H, Ar); 8.00-8.08 (m, 1H, Ar); 8.32-8.40 (m, 1H, Ar).

4-Chloro-2-cycloheptyl-1*H*-imidazo[4,5-*c*]quinoline (compound 27).

Scale: 0.8 mmol. Yield: 0.38 g (86%). Mp.: 195-200 °C. MS (ESI) *m/z* 299.9 (M + 1)⁺, 301.7 (M + 3)⁺. ¹H NMR (CD₃OD): δ 1.73-2.13 (m, 12H, 6 CH₂); 3.21-3.40 (m, 1H, CH); 7.63-7.79 (m, 2H, Ar); 7.97-8.05 (m, 1H, Ar); 8.29-8.38 (m, 1H, Ar).

- 27 -

4-Chloro-2-furyl-1H-imidazo[4,5-c]quinoline (compound 28).

Scale: 1.4 mmol. Eluent for column chromatography was petroleum ether:ethyl acetate: = 75:25. Yield: 0.1 g (26%). Mp.: 235-238 °C. MS (ESI) m/z 269.8 (M + 1)⁺, 272.1 (M + 3)⁺. ¹H NMR (CD₃OD): 6.72-6.75 (m, 1H, Ar); 7.40-7.43 (m, 1H, Ar); 7.63-7.75 (m, 2H, Ar); 7.83-7.88 (m, 1H, Ar); 7.98-8.01 (m, 1H, Ar); 8.36-8.40 (m, 1H, Ar).

4-Chloro-2-pentyl-1H-imidazo[4,5-c]quinoline (compound 29).

Scale: 0.45 mmol. Yield: 0.052 g (41%): mp 236-237 °C; MS (ESI) m/z 273.9 (M + 1)⁺, ¹H NMR (CDCl₃): δ 0.65-0.72 (t, 3H, CH₃, J = 6 Hz); 1.14-1.21 (m, 4H, 2 × CH₂); 1.61-1.72 (m, 2H, CH₂); 2.76-2.84 (t, 2H, CH₂, J = 8 Hz); 7.33-7.47 (m, 2H, Ar); 7.76-7.80 (m, 1H, Ar); 7.95-8.15 (m, 1H, Ar).

General procedure of N-substituted 1H-imidazo[4,5-c]quinolin-4-amines (compounds 30-47)

These compounds were prepared by means of microwave-assisted chemistry. Absolute ethanol (2.5-3.0 ml) was added to the appropriate 4-chloro-1H-imidazo[4,5-c]quinoline and appropriate aniline (2-3 eq.). Conditions: pre stirring 60 seconds, temperature 120 °C, time 2400 seconds, normal sample absorption, fixed hold time. After the reaction was completed the solvent was evaporated and the remaining product was purified by column chromatography and recrystallized.

N-Phenyl-2-cyclopentyl-1H-imidazo[4,5-c]quinolin-4-amine (compound 30).

Compound 30 was prepared as described elsewhere [Van Galen P.J.M. et al. (1991) *ibid.*].

Scale: 0.8 mmol. Eluent for column chromatography was 2.5-10% methanol in dichloromethane. Yield: 40 mg (15%). The product was recrystallized from methanol. Mp.: 155-157 °C. MS (ESI) m/z 328.9 (M + 1)⁺. ¹H NMR (CDCl₃): δ 1.80-2.27 (m, 8H, 4 CH₂); 3.31-3.55 (m, 1H, CH); 7.00-7.09 (m, 1H, Ar); 7.15-7.29 (m, 4H, Ar); 7.49-7.56 (m, 1H, Ar); 7.78 (d, 1H, J = 6.6 Hz, Ar); 7.96-8.09 (m, 2H, Ar). ¹³C NMR 750 MHz (CDCl₃): δ 24.9, 31.7, 38.9, 114.7, 117.9, 118.1, 118.3, 119.2, 119.8, 120.9, 121.9,

- 28 -

123.6, 124.1, 126.2, 126.4, 126.5, 126.7, 128.1, 128.2, 128.9, 133.5, 140.5, 143.3, 146.6, 156.3, 159.1. Anal. (C₂₁H₂₀N₄·0.7H₂O) C, H, N.

***N*-(4-Methyl-phenyl)-2-cyclopentyl-1*H*-imidazo[4,5-*c*]quinolin-4-amine (compound 31).**

Scale: 0.7 mmol. Eluent for column chromatography was 1% methanol in dichloromethane. Yield: 80 mg (35%). The product was recrystallized from methanol. Mp.: 125-126 °C. MS (ESI) *m/z* 342.7 (M + 1)⁺, 343.8 (M + 2)⁺. ¹H NMR (CDCl₃): δ 1.55-2.15 (m, 8H, 4 CH₂); 2.24 (s, 3H, CH₃); 3.21-3.33 (m, 1H, CH); 7.07 (d, 2H, *J* = 8.0 Hz, Ar); 7.21-7.28 (m, 1H, Ar); 7.46 (t, 1H, *J* = 7.3 Hz, Ar); 7.74-7.87 (m, 4H, Ar). ¹³C NMR 400 MHz (CDCl₃): δ 20.7, 24.4, 29.7, 32.4, 39.6, 62.5, 115.8, 120.7, 122.6, 126.7, 127.3, 129.4, 132.4, 137.1, 143.8, 147.5, 157.1. Anal. (C₂₂H₂₂N₄·1.7H₂O) C, H, N.

***N*-(4-Methoxy-phenyl)-2-cyclopentyl-1*H*-imidazo[4,5-*c*]quinolin-4-amine (compound 32).**

Scale: 0.7 mmol. Eluent for column chromatography was 1% methanol in dichloromethane. Yield: 90 mg (38%). The product was recrystallized from methanol. Mp.: 106-107 °C; MS (ESI) *m/z* 358.8 (M + 1)⁺. ¹H NMR (CDCl₃): δ 1.71-2.29 (m, 8H, 4 CH₂); 3.22-3.38 (m, 1H, CH); 3.65 (s, 3H, OCH₃); 6.80-6.84 (m, 2H, Ar); 7.26 (t, 1H, *J* = 8.0 Hz, Ar); 7.46 (t, 1H, *J* = 7.3 Hz, Ar); 7.76-7.93 (m, 4H, Ar). ¹³C NMR 400 MHz (CDCl₃): δ 25.5, 32.5, 39.6, 53.4, 55.4, 114.2, 114.8, 116.5, 120.4, 122.1, 122.4, 127.0, 127.2, 133.1, 144.0, 147.8, 155.4, 156.7. Anal. (C₂₂H₂₂N₄O·CH₃OH) C, H, N.

***N*-(3,4-Dichloro-phenyl)-2-cyclopentyl-1*H*-imidazo[4,5-*c*]quinolin-4-amine (compound 33).**

Scale: 0.7 mmol. Eluent for column chromatography was dichloromethane. Polarity was slowly increased with methanol till 2%. Yield: 150 mg (54%). The product was recrystallized from methanol. Mp.: 114-115 °C. MS (ESI) *m/z* 396.5 (M + 1)⁺, 398.5 (M + 2)⁺, 400.5 (M + 3)⁺. ¹H NMR (CDCl₃): δ 1.68-2.29 (m, 8H, 4 CH₂); 3.29-3.43 (m, 1H, CH); 7.33 (t, 2H, *J* = 8.8 Hz, Ar); 7.54 (t, 1H, *J* = 8.0 Hz, Ar); 7.78 (t, 2H,

- 29 -

$J = 8.0$ Hz, Ar); 7.99 (d, 1H, $J = 8.0$ Hz, Ar); 8.44 (s, 1H, Ar); 9.62 (broad s, 1H, NH).
Anal. ($C_{21}H_{18}Cl_2N_4 \cdot 2.2 H_2O$) C, H, N.

***N*-(4-Chloro-phenyl)-2-cyclopentyl-1*H*-imidazo[4,5-*c*]quinolin-4-amine (compound 34).**

Scale: 1.0 mmol. Eluent for column chromatography was 0.5-2% methanol in dichloromethane. Yield: 120 mg (33%). The product was recrystallized from methanol. Mp.: 189-190 °C. MS (ESI) m/z 362.7 ($M + 1$)⁺, 365.0 ($M + 3$)⁺. ¹H NMR ($CDCl_3$): δ 1.67-2.25 (m, 8H, 4 CH₂); 3.28-3.43 (m, 1H, CH); 7.27-7.39 (m, 3H, Ar); 7.49-7.59 (m, 1H, Ar); 7.71-7.79 (m, 1H, Ar); 7.97 (t, 3H, $J = 8.0$ Hz, Ar); 8.46 (broad s, 1H, NH).
Anal. ($C_{21}H_{19}ClN_4 \cdot 1.5 H_2O$) C, H, N.

***N*-(3-Methanol-phenyl)-2-cyclopentyl-1*H*-imidazo[4,5-*c*]quinolin-4-amine (compound 35).**

Scale: 0.4 mmol. Eluent for column chromatography was ethyl acetate:petroleum ether = 50:50, later increased to 70:30 respectively. Yield: 33 mg (25%). The product was recrystallized from methanol giving off-white crystals. Mp.: 228-230 °C. MS (ESI) m/z 359.0 ($M + 1$)⁺. ¹H NMR ($CDCl_3/ CD_3OD$): δ 1.63-2.16 (m, 8H, 4 CH₂); 3.23-3.24 (m, 1H, CH); 3.95-4.05 (q, 2H, $J = 7.3$ Hz, CH₂); 6.93 (d, 1H, $J = 8.0$ Hz, Ar); 7.18-7.28 (m, 3H, Ar); 7.39 (t, 1H, $J = 7.3$ Hz, Ar); 7.72-7.92 (m, 3H, Ar, OH). Anal. ($C_{22}H_{22}N_4O \cdot 0.5 CH_3OH$) C, H, N.

***N*-([3,4-*c*]Indan)-2-cyclopentyl-1*H*-imidazo[4,5-*c*]quinolin-4-amine (compound 36).**

Scale: 0.4 mmol. Eluent for column chromatography was 1% methanol in dichloromethane. Yield: 120 mg (81%). The product was recrystallized from methanol giving light brown crystals. Mp.: 142-145 °C. MS (ESI) m/z 369.0 ($M + 1$)⁺. ¹H NMR ($CDCl_3$): δ 1.15-1.34 (m, 2H, CH₂); 1.65-2.19 (m, 8H, 4 CH₂); 2.76 (t, 4H, $J = 7.3$ Hz, 2 CH₂); 3.24-3.27 (m, 1H, CH); 7.06 (d, 1H, $J = 8.0$ Hz, Ar); 7.22-7.29 (m, 1H, Ar); 7.40-7.49 (m, 2H, Ar); 7.73 (s, 1H, Ar); 7.85-7.96 (m, 2H, Ar). Anal. ($C_{24}H_{24}N_4 \cdot 1.2 H_2O$) C, H, N.

- 30 -

***N*-(1*H*-indazol-6-yl)-2-cyclopentyl-1*H*-imidazo[4,5-*c*]quinolin-4-amine (compound 37).**

Scale: 0.4 mmol. Eluent for column chromatography was ethylacetate:petroleumether = 80:20. Yield: 110 mg (74%). The product was recrystallized from ethyl acetate:petroleum ether = 50:50 giving off-white crystals. Mp.: 235-236 °C. MS (ESI) m/z 368.8 ($M + 1$)⁺. ¹H NMR (CD₃OD): δ 1.70-2.38 (m, 8H, 4 CH₂); 3.23-3.50 (m, 1H, CH); 7.31-7.38 (m, 1H, Ar); 7.47-7.60 (m, 2H, Ar); 7.71-7.75 (m, 1H, Ar); 7.82-7.86 (m, 1H, Ar); 8.01-8.08 (m, 2H, Ar); 8.68 (s, 1H, Ar). Anal. (C₂₂H₂₀N₆·1.5 H₂O) C, H, N.

***N*-(4-Methoxy-benzyl)-2-cyclopentyl-1*H*-imidazo[4,5-*c*]quinolin-4-amine (compound 38).**

Scale: 0.4 mmol. Eluent for column chromatography was diisopropylether. Yield: 33 mg (22%). The product was recrystallized from methanol giving white crystals. Mp.: 245-247 °C. MS (ESI) m/z 372.9 ($M + 1$)⁺. ¹H NMR (CD₃OD): δ 1.72-2.30 (m, 8H, 4 CH₂); 3.26-3.41 (m, 1H, CH); 3.77 (s, 3H, OCH₃); 4.76 (s, 2H, CH₂); 6.87-6.92 (m, 2H, Ar); 7.23-7.49 (m, 4H, Ar); 7.78 (d, 1H, $J = 8.8$ Hz, Ar); 8.00 (d, 1H, $J = 7.3$ Hz, Ar). Anal. (C₂₃H₂₄N₄O) C, H, N.

***N*-(1*H*-Indol-6-yl)-2-cyclopentyl-1*H*-imidazo[4,5-*c*]quinolin-4-amine (compound 39).**

Scale: 0.4 mmol. Eluent for column chromatography was ethyl acetate:petroleum ether = 20:80, increased to 30:70. Yield: 30 mg (20%). The product was recrystallized from methanol giving light grey crystals. Mp.: 260-261 °C. MS (ESI) m/z 368.0 ($M + 1$)⁺. ¹H NMR (CD₃OD): δ 1.79-2.29 (m, 8H, 4 CH₂); 3.30-3.46 (m, 1H, CH); 6.45 (d, 1H, $J = 2.9$ Hz, Ar); 7.23-7.50 (m, 5H, Ar); 7.77 (d, 1H, $J = 7.8$ Hz, Ar); 8.01 (d, 1H, $J = 8.0$ Hz, Ar); 8.20 (s, 1H, Ar). Anal. (C₂₃H₂₁N₅) C, H, N.

***N*-(Benzyl)-2-cyclopentyl-1*H*-imidazo[4,5-*c*]quinolin-4-amine (compound 40).**

Scale: 0.8 mmol. Eluent for column chromatography was 2% methanol in dichloromethane. Yield: 0.07 mg (25%). The product was oily. ¹H NMR (CDCl₃): δ 1.50-2.11 (m, 8H, 4 CH₂); 3.14-3.31 (m, 1H, CH); 4.85 (s, 2H, CH₂); 6.25 (broad s, 2H,

- 31 -

2 NH); 7.08-7.20 (m, 6H, Ar); 7.38 (t, 1H, $J = 8.8$ Hz, Ar); 7.87 (d, 1H, $J = 8.8$ Hz, Ar); 8.09 (d, 1H, $J = 8.0$ Hz, Ar). ^{13}C NMR (CDCl_3): δ 25.3, 32.3, 39.7, 45.4, 116.1, 121.3, 122.2, 125.3, 127.0, 127.4, 128.1, 138.1, 143.3, 144.0, 149.7, 157.4, 160.6. Anal. ($\text{C}_{22}\text{H}_{22}\text{N}_4$) C, H, N.

***N*-(Phenylethyl)-2-cyclopentyl-1*H*-imidazo[4,5-*c*]quinolin-4-amine (compound 41).**

Scale: 0.8 mmol. Eluent for column chromatography was 1% methanol (increased to 4%) in dichloromethane. Yield: 160 mg (56%). The product was recrystallized from absolute methanol giving off-white crystals: mp 95-97 °C; MS (ESI) m/z 356.9 ($\text{M} + 1$)⁺, 357.7 ($\text{M} + 2$)⁺, 359.0 ($\text{M} + 3$)⁺. ^1H NMR (CD_3OD): δ 1.75-2.21 (m, 8H, 4 CH_2); 3.02 (t, 2H, $J = 8.0$ Hz, CH_2); 3.30-3.38 (m, 1H, CH); 3.89 (t, 2H, $J = 8.0$ Hz, CH_2); 7.15-7.45 (m, 7H, Ar); 7.76 (d, 1H, $J = 8.8$ Hz, Ar); 7.97 (d, 1H, $J = 6.3$ Hz, Ar). ^{13}C NMR (CD_3OD): δ 27.6, 29.0, 34.9, 41.6, 116.8, 119.1, 121.1, 121.6, 124.2, 125.1, 128.2, 128.3, 131.2, 133.3, 141.7, 144.4, 147.3, 160.1. Anal. ($\text{C}_{23}\text{H}_{24}\text{N}_4$) C, H, N.

***N*-(3,4-Dichloro-phenyl)-2-cycloheptyl-1*H*-imidazo[4,5-*c*]quinolin-4-amine (compound 42).**

Scale: 0.8 mmol. Eluent for column chromatography was ethyl acetate:petroleum ether = 70:90, increased to 100% ethyl acetate. Yield: 164 mg (50%). The product was recrystallized from methanol giving off-white crystals. Mp.: 236-238 °C. MS (ESI) m/z 424.9 ($\text{M} + 1$)⁺, 426.8 ($\text{M} + 2$)⁺, 428.1 ($\text{M} + 3$)⁺. ^1H NMR ($\text{CDCl}_3/\text{CD}_3\text{OD}$ 9/1, v/v): δ 1.62-2.00 (m, 10H, 5 CH_2); 2.17-2.24 (m, 2H, CH_2); 3.09-3.23 (m, 1H, CH); 7.32-7.39 (m, 2H, Ar); 7.50-7.58 (m, 1H, Ar); 7.71-7.85 (m, 2H, Ar); 7.98 (d, 1H, $J = 8.0$ Hz, Ar); 8.41 (s, 1H, Ar). ^{13}C NMR ($\text{DMSO}-d_6$): δ 26.2, 27.7, 33.4, 40.2, 115.2, 119.3, 120.2, 121.0, 122.0, 122.9, 127.0, 128.3, 130.1, 130.6, 134.2, 141.6, 142.7, 146.8, 158.6. Anal. ($\text{C}_{23}\text{H}_{22}\text{Cl}_2\text{N}_4 \cdot 1.3 \text{H}_2\text{O}$) C, H, N.

***N*-(3,4-Dichloro-phenyl)-2-furyl-1*H*-imidazo[4,5-*c*]quinolin-4-amine (compound 43).**

Scale: 0.4 mmol. Eluent for column chromatography was ethyl acetate:petroleum ether = 20:80. Yield: 96 mg (64%). The product was recrystallized from methanol giving orange crystals. Mp.: 135-138 °C. MS (ESI) m/z 394.7 ($\text{M} + 1$)⁺,

- 32 -

396.7 (M + 3)⁺. ¹H NMR (CD₃OD): δ 6.64-6.67 (m, 1H, Ar); 7.10 (d, 1H, *J* = 3.7 Hz, Ar); 7.21-7.44 (m, 4H, Ar); 7.65-7.72 (m, 2H, Ar); 7.95 (d, 1H, *J* = 8.0 Hz, Ar); 8.43-8.44 (m, 1H, Ar). ¹³C NMR (DMSO-*d*₆): δ 110.6, 112.6, 115.3, 119.5, 120.4, 121.5, 122.2, 123.2, 127.1, 127.6, 128.2, 130.1, 130.3, 130.6, 134.6, 141.5, 142.3, 143.2, 144.7, 145.1, 146.9. Anal. (C₂₀H₁₂Cl₂N₄O·0.5 H₂O) C, H, N.

***N*-(3,4-Dichloro-phenyl)-2-cyclobutyl-1*H*-imidazo[4,5-*c*]quinolin-4-amine (compound 44).**

Scale: 0.7 mmol. Eluent for column chromatography was ethyl acetate:petroleum ether = 20:80. Yield: 121 mg (48%). The product was recrystallized from methanol:ethyl acetate = 20:80 giving off-white crystals. Mp.: 131-134 °C. MS (ESI) *m/z* 382.8 (M + 1)⁺. ¹H NMR (CD₃OD): δ 2.00-2.22 (m, 2H, CH₂); 2.42-2.56 (m, 4H, 2 CH₂); 3.72-3.89 (m, 1H, CH); 7.26-7.33 (m, 2H, Ar); 7.47-7.54 (m, 1H, Ar); 7.64-7.69 (m, 1H, Ar); 7.88-7.96 (m, 2H, Ar); 8.30 (s, 1H, Ar). Anal. (C₂₀H₁₆Cl₂N₄·1.0 MeOH) C, H, N.

***N*-(3,4-Dichloro-phenyl)-2-cyclohexyl-1*H*-imidazo[4,5-*c*]quinolin-4-amine (compound 45).**

Scale: 0.9 mmol. Eluent for column chromatography was ethyl acetate:petroleum ether = 15:85, increased to 30:70. Yield: 160 mg (44%). The product was recrystallized from methanol:ethyl acetate = 1:99 giving off-white crystals. Mp.: 237-240 °C. MS (ESI) *m/z* 410.8 (M + 1)⁺, 412.7 (M + 2)⁺, 414.7 (M + 3)⁺. ¹H NMR (CD₃OD): δ 1.40-2.00 (m, 8H, 4 CH₂); 2.15-2.28 (m, 2H, CH₂); 2.95-3.07 (m, 1H, CH); 7.34-7.56 (m, 4H, Ar); 7.77-7.88 (m, 2H, Ar); 8.52 (s, 1H, Ar). ¹³C NMR (DMSO-*d*₆): δ 25.6, 31.6, 38.2, 115.5, 119.2, 120.1, 121.1, 122.0, 123.0, 127.0, 130.1, 130.6, 134.1, 141.6, 142.7, 146.7, 153.2, 157.5. Anal. (C₂₂H₂₀Cl₂N₄·2.1 H₂O) C, H, N.

***N*-(3,4-Dichloro-phenyl)-2-1*H*-imidazo[4,5-*c*]quinolin-4-amine (compound 46).**

Scale: 1.0 mmol. Eluent for column chromatography was ethyl acetate:petroleum ether = 20:80. Yield: 160 mg (50%). The product was recrystallized from ethyl acetate:petroleum ether = 30:70 giving white crystals. Mp.: 167-172 °C. MS (ESI) *m/z* 328.9 (M + 1)⁺, 331.0 (M + 2)⁺, 332.0 (M + 3)⁺. ¹H NMR (CDCl₃): δ 7.23-

- 33 -

7.36 (m, 2H, Ar); 7.39-7.43 (m, 1H, Ar); 7.62-7.72 (m, 1H, Ar); 7.65-7.95 (m, 3H, Ar); 8.32 (s, 1H, Ar). Anal. (C₁₆H₁₀Cl₂N₄·1.1 H₂O) C, H, N.







***N*-(3,4-Dichloro-phenyl)-2-pentyl-1*H*-imidazo[4,5-*c*]quinolin-4-amine (compound 47).**

Scale: 0.2 mmol. Eluent for column chromatography was dichloromethane. Yield: 44 mg (73%). The product was recrystallized from ethyl acetate:petroleum ether = 50:50 giving white crystals. Mp.: 195-200 °C. MS (ESI) *m/z* 398.9 (M + 1)⁺, 400.8 (M + 3)⁺. ¹H NMR (CDCl₃): δ 0.82-0.97 (m, 3H, CH₃); 1.39-1.51 (m, 2H, CH₂); 1.81- (m, 4H, 2 CH₂); 2.98 (t, 2H, *J* = 8.0 Hz, CH₂); 7.33-7.41 (m, 2H, Ar); 7.52-7.60 (m, 1H, Ar); 7.74-7.81 (m, 2H, Ar); 7.99 (d, 1H, *J* = 8.0 Hz, Ar); 8.48 (s, 1H, Ar). Anal. (C₂₁H₂₀Cl₂N₄) C, H, N.









Table 1 summarizes the chemical structures and physico-chemical characteristics of the imidazoquinoline derivatives prepared as described above.

- 34 -





Table 1: Chemical structures and physico-chemical characteristics

Nr	Compound	Molecular Formula	MW	Mp (°C)	MS	Recrystall-ization. solvent
30		C ₂₁ H ₂₀ N ₄	328.42	155-157	328.9	MeOH
31		C ₂₂ H ₂₂ N ₄	342.45	125-126	342.7 343.8	MeOH
32		C ₂₂ H ₂₂ N ₄ O	358.45	106-107	358.8	MeOH
33		C ₂₁ H ₁₈ Cl ₂ N ₄	397.31	114-115	396.5	MeOH
34		C ₂₁ H ₁₉ ClN ₄	362.87	189-190	362.7	MeOH
35		C ₂₂ H ₂₂ N ₄ O	358.45	228-230	359.0	MeOH

- 35 -

Nr	Compound	Molecular Formula	MW	Mp (°C)	MS	Recrystall-ization. solvent
36		C ₂₄ H ₂₄ N ₄	368.49	142-145	369.0	MeOH
37		C ₂₂ H ₂₀ N ₆	368.44	235-236	368.8	50/50 EA/PE
38		C ₂₃ H ₂₄ N ₄ O	372.47	245-247	372.9	MeOH
39		C ₂₃ H ₂₁ N ₅	367.46	260-261	368.0	MeOH
40		C ₂₂ H ₂₂ N ₄	342.45	-	-	oil
41		C ₂₃ H ₂₄ N ₄	356.47	95-97	356.9 357.7 359.0	MeOH
42		C ₂₃ H ₂₂ Cl ₂ N ₄	425.36	236-238	424.9 426.8	MeOH
43		C ₂₀ H ₁₂ Cl ₂ N ₄ O	395.25	135-138	394.7 396.7	MeOH

- 36 -

Nr	Compound	Molecular Formula	MW	Mp (°C)	MS	Recrystall-ization. solvent
44		C ₂₀ H ₁₆ Cl ₂ N ₄	383.28	131-134	382.8 386.9	20/80 MeOH/EA
45		C ₂₂ H ₂₀ Cl ₂ N ₄	411.34	237-340	410.8 412.7 414.7	EA + 1% MeOH
46		C ₁₆ H ₁₀ Cl ₂ N ₄	329.19	167-172	328.9 331.0 332.0	30/70 PE/EA
47		C ₂₁ H ₂₀ Cl ₂ N ₄	399.33	195-200	398.9 400.8	50/50 EA/PE

MW: molecular weight (D); Mp: melting point (°C); MS: mass spectrometry data (M+1, M+2, M+3)

Biological Experiments

Material:

[¹²⁵I]N⁶-(4-amino-3-iodobenzyl)adenosine-5'-N-methyluronamide (I-AB-MECA; 2000 Ci/mmol), [³H]R-PIA (R-N⁶-[phenylisopropyl]adenosine, 34 Ci/mmol), [³H]CGS21680 (2-[p-(2-carboxyethyl)phenylethylamino]-5'-N-ethylcarboxamido-adenosine, 47 Ci/mmol) and [³H]cyclic AMP (40 Ci/mmol) were from Amersham Pharmacia Biotech (Buckinghamshire, UK).

Cell culture and membrane preparation:

CHO (Chinese hamster ovary) cells expressing the recombinant human ARs (HEK-293 cells were used for the human A_{2A}AR) were cultured in DMEM and F12 (1:1) supplemented with 10% fetal bovine serum, 100 units/ml penicillin, 100 µg/ml streptomycin and 2 µmol/ml glutamine. Cells were harvested by trypsinization. After

- 37 -

homogenization and suspension, cells were centrifuged at 500 g for 10 min, and the pellet was re-suspended in 50 mM Tris·HCl buffer (pH 7.4) containing 10 mM MgCl₂. The suspension was homogenized with an electric homogenizer for 10 sec, and was then re-centrifuged at 20,000 g for 20 min at 4°C. The resultant pellets were resuspended in buffer in the presence of 3 Units/mL adenosine deaminase, and the suspension was stored at -80°C until the binding experiments. The protein concentration was measured using the Bradford assay.

Binding Assays to the Human A₁ and A_{2A} ARs:

For binding to the human A₁ AR, [³H]R-PIA (2 nM) was incubated with membranes (40 µg/tube) from CHO cells stably expressing the human A₁ AR at 25°C for 60 min in 50 mM Tris·HCl buffer (pH 7.4; MgCl₂, 10 mM) in a total assay volume of 200 µL. Nonspecific binding was determined using 10 µM of N⁶-cyclopentyladenosine. For human A_{2A} AR binding, membranes (20 µg/tube) from HEK-293 cells stably expressing the human A_{2A} AR were incubated with 15 nM [³H]CGS21680 at 25 °C for 60 min in 200 µL of 50 mM Tris·HCl, pH 7.4, containing 10 mM MgCl₂. N-5'-ethyluronamidoadenosine (10 µM) was used to define nonspecific binding. Reaction was terminated by filtration with GF/B filters.

Binding Assay to the Human A₃ AR:

Each tube in the competitive binding assay contained 100 µl membrane suspension (20 µg protein), 50 µl [¹²⁵I]I-AB-MECA (0.5 nM), and 50 µl of increasing concentrations of the test ligands in Tris·HCl buffer (50 mM, pH 8.0) containing 10 mM MgCl₂, 1 mM EDTA. Nonspecific binding was determined using 10 µM of 5'-N-ethylcarboxamidoadenosine in the buffer. The mixtures were incubated at 25°C for 60 min. Binding reactions were terminated by filtration through Whatman GF/B filters under reduced pressure using a MT-24 cell harvester (Brandell, Gaithersburgh, MD, USA). Filters were washed three times with 9 mL ice-cold buffer. Radioactivity was determined in a Beckman 5500B γ-counter.

Dissociation kinetics of [¹²⁵I]I-AB-MECA from human A₃ARs:

The dissociation of [¹²⁵I]I-AB-MECA was measured as follows. Membranes (20 µg) were preincubated at 25°C with 0.5 nM [¹²⁵I]I-AB-MECA, in a total volume of

- 38 -

100 μ l of Tris-HCl buffer (50 mM, pH 8.0) containing 10 mM $MgCl_2$, and 1 mM EDTA for 60 min. The dissociation was then initiated by the addition of 3 μ M CI-IB-MECA with or without allosteric modulators. The time course of dissociation of total binding was measured by rapid filtration at appropriate time intervals. Nonspecific binding was measured after 60-min incubation in the presence of 3 μ M CI-IB-MECA. Further assay was as described above.

Cyclic AMP accumulation assay:





Intracellular cyclic AMP levels were measured with a competitive protein binding method (Nordstedt and Fredholm, 1990). CHO cells that expressed recombinant human A_3ARs were harvested by trypsinization. After centrifugation and resuspension in medium, cells were plated in 24-well plates in 0.5 ml medium. After 24 hr, the medium was removed and cells were washed three times with 1 ml DMEM, containing 50 mM HEPES, pH 7.4. Cells were then treated with agonists and/or test compounds in the presence of rolipram (10 μ M) and adenosine deaminase (3 units/ml). After 45 min forskolin (10 μ M) was added to the medium, and incubation was continued an additional 15 min. The reaction was terminated by removing the supernatant, and cells were lysed upon the addition of 200 μ L of 0.1 M ice-cold HCl. The cell lysate was resuspended and stored at $-20^\circ C$. For determination of cyclic AMP production, protein kinase A (PKA) was incubated with [3H]cyclic AMP (2 nM) in K_2HPO_4 /EDTA buffer (K_2HPO_4 , 150 mM; EDTA, 10 mM), 20 μ L of the cell lysate, and 30 μ L 0.1 M HCl or 50 μ L of cyclic AMP solution (0-16 pmol/200 μ L for standard curve). Bound radioactivity was separated by rapid filtration through Whatman GF/C filters and washed once with cold buffer. Bound radioactivity was measured by liquid scintillation spectrometry.

Statistical analysis

Binding and functional parameters were calculated using Prism 5.0 software (GraphPAD, San Diego, CA, USA). IC_{50} values obtained from competition curves were converted to K_i values using the Cheng-Prusoff equation. Data were expressed as mean \pm standard error.

Table 2: Potency of 1H-imidazo-[4,5-c]quinolin-4-amine derivatives in binding or activation assays at human A₁, A_{2A}, A_{2B} and A₃ARs and allosteric effects at the human A₃AR

No.	R ₁	R ₂	K _i (hA ₁ AR), nM ^a or % displ. at 10 μM	K _i (hA _{2A} AR), nM ^a or % displ. at 10 μM	hA _{2B} AR ^b % inhib. at 10 μM	K _i (hA ₃ AR), nM ^a or % displ. at 10 μM	hA ₃ AR ag. Dissociation ^c at 10 μM	% Increase of efficacy at hA ₃ AR ^d at 10 μM
30	Ph	CP	3420 ± 230	3150 ± 210	-6.8%	786 ± 67 (90%)	174 ± 5	138 ± 8
31	4-CH ₃ -Ph	CP	3850 ± 500	5220 ± 320	-4.1%	1190 ± 107 (87%)	153 ± 4	128 ± 4
32	4-CH ₃ O-Ph	CP	4170 ± 730	>10,000 (16%)	7.3%	410 ± 64 (92%)	166 ± 11	132 ± 4
33	3,4-Cl ₂ -Ph	CP	>10,000 (15%)	>10,000 (0%)	-6.7%	4690 ± 970 (67%)	144 ± 9	141 ± 5
34	4-Cl-Ph	CP	>10,000 (22%)	>10,000 (17%)	-10.2%	1610 ± 550 (82%)	159 ± 5	136 ± 3
35	3-HOCH ₂ -Ph	CP	51%	49%	-4.1%	56%	129 ± 15	118 ± 4

36		CP	21%	8%	-10.7%	69%	108±4	111±5
37		CP	56%	68%	5.0%	67%	109±3	96±2
38	4-CH ₃ O- PhCH ₂	CP	59%	60%	0.3%	80%	101±13	109±3
39		CP	70%	74%	10.1%	89%	126±9	125±2
40	PhCH ₂	CP	28%	77%	-3.4%	86%	145±10	147±8
41	Ph(CH ₂) ₂	CP	52%	91%	-11.6%	84%	154±7	137±4
42	3,4-Cl ₂ -Ph cycloheptyl		-4%	-2%	-7.3%	68%	130±2	115±7
43	3,4-Cl ₂ -Ph 		-4%	70%	9.0%	78%	98±3	95±4
44	3,4-Cl ₂ -Ph cyclobutyl		-5%	0.4%	-5.5%	52%	116±3	126±3

45	3,4-Cl ₂ -Ph	cyclohexyl	-2%	-1%	-5.6%	45%	173±5	145±7
46	3,4-Cl ₂ -Ph	H	1.8%	-0.8%	10.2%	39%	91±7	92±4
47	3,4-Cl ₂ -Ph	<i>n</i> -pentyl	43.9%	-1%	-9.3%	84%	116±5	102±5

a) All experiments were performed using adherent CHO (A₁ and A₃) and HEK293 (A_{2A}) cells stably transfected with cDNA encoding the human ARs. Binding at human A₁, A_{2A} and A₃ ARs in this study was carried out as described in Methods using [³H]R-PIA (2.0 nM), [³H]CGS 21680 (15 nM) or [¹²⁵I]-AB-MECA (0.5 nM) as a radioligand. Values from the present study are expressed as mean ± s.e.m., n = 3-5. Percentage inhibition at A₁, A_{2A}, or A₃ receptors is expressed as the mean value from 2-4 separate experiments with similar results performed in duplicate.

b) A_{2B} receptor: effect of compounds at 10 μM on NECA (150 nM)-induced cyclic AMP accumulation from one experiment performed in triplicate; the inhibition of CGS15943 (10 μM) was expressed as 100%.

c) dissociation: % decrease of dissociation at 30 min; the residual binding of [¹²⁵I]-AB-MECA after 30 min of dissociation was expressed as 100%.

d) increase of efficacy: compared to maximal effect by 2-Cl-IB-MECA alone (control = 100%)

- 42 -

In **Table 2** the effects of the imidazoquinoline derivatives at the orthosteric sites of all four adenosine receptor subtypes were listed, together with their effects on the allosteric site on the human adenosine A_3 receptor. Many compounds display little if any affinity for the orthosteric binding sites, particularly on the adenosine A_1 , A_{2A} and A_{2B} receptor, especially when $R_1 = 3,4\text{-Cl}_2\text{-phenyl}$. Also the orthosteric binding site on the adenosine A_3 receptor accommodates the imidazoquinoline derivatives rather poorly. The best separation between orthosteric and allosteric recognition was found with compound **45**. Thus, this compound was selected for further *in vivo* assays.

In vivo evaluation of imidazoquinoline derivative **45** potency as an A_3AM :

A. Inhibitory activity of imidazoquinoline derivative **45** on myeloid system:

A stock solution of imidazoquinoline derivative **45** was prepared by dissolving the same in DMSO. Further dilutions for treatment were performed in PBS. As a control, an equivalent amount of DMSO in PBS was used.

To test the effect of imidazoquinoline derivative **45** on the myeloid system, the compound was orally administered at a dose of 100 $\mu\text{g}/\text{kg}$, thrice daily to ICR mice, for two consecutive days. Blood samples were withdrawn 24 and 48 hours after the last drug administration. A differential blood count was performed.

The results presented in **Figures 2A-2B** show that imidazoquinoline derivative **45** enhanced the myeloid system of naïve mice, which was demonstrated by the increased number of white blood cells (WBC) and neutrophils following treatment therewith.

B. Effect of imidazoquinoline derivative **45** on the development of Adjuvant Induced Arthritis AIA:

Adjuvant induced arthritis model (model for rheumatoid arthritis (RA)) was established in rats by immunizing the animals with an emulsion contacting *Mycobacterium tuberculosis* in Freund's adjuvant (Animal Models for Autoimmune and Inflammatory disease: Adjuvant Arthritis in the Rat. Current Protocols in Immunology, Supplement 19, page 15.4.2.). Treatment with imidazoquinoline derivative **45** was

- 43 -

initiated upon onset of disease. The imidazoquinoline derivative **45** was administered orally twice daily at a dose of 100 µg/kg.


Evaluation of disease development was carried out daily, starting upon onset of disease until the end of the study. Intensity of arthritis was scored by grading each paw from 0-4 on erythema, swelling and deformity of the joint, every day: **0** = no erythema or swelling; **1** = slight erythema or swelling of one of the toes or fingers; **2** = erythema and swelling of more than one toe or finger; **3** = erythema and swelling of the ankle or wrist; **4** = complete erythema and swelling of toes or fingers and ankles or wrist, and inability to bend the ankle or wrist. All scores of the four legs from each rat are added to give up to a maximum arthritic score of 16. The results are presented in **Figure 3** which show the reduction in clinical score following treatment with imidazoquinoline derivative **45**.

The results presented above suggest that the imidazoquinoline derivative and in the particular example imidazoquinoline derivative **45** may have a dual effect, on the one hand of enhancing the myeloid system and on the other hand, as a remedy for conditions such as RA.

- 44 -

CLAIMS:

1. Use of an A₃ adenosine receptor allosteric modulator (A₃RM), having the following general formula (I):



Formula I

wherein:


- **R₁** represents an aryl or alkaryl being optionally substituted at the aromatic ring once or more with a substituent selected C₁-C₁₀ alkyl, halo, C₁-C₁₀ alkanol, hydroxyl, C₁-C₁₀ acyl, C₁-C₁₀ alkoxy; C₁-C₁₀-alkoxycarbonyl, C₁-C₁₀ alkoxyalkyl; C₁-C₁₀ thioalkoxy; C₁-C₁₀ alkylether, amino, hydrazido, C₁-C₁₀ alkylamino, pyridylthio, C₂-C₁₀ alkenyl; C₂-C₁₀ alkynyl, thio, and C₁-C₁₀ alkylthio, acetoamido, sulfonic acid; or said substituents can form together a cycloalkyl or cycloalkenyl fused to said aryl, the cycloalkyl or cycloalkenyl optionally comprising one or more heteroatoms; provided that said aryl is not an unsubstituted phenyl group;
- **R₂** represents hydrogen or a substituent selected from C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl; C₂-C₁₀ alkynyl, C₄-C₁₀ cycloalkyl, C₄-C₁₀ cycloalkenyl or a five to seven membered heterocyclic aromatic ring, C₅-C₁₅ fused cycloalkyl, bicyclic aromatic or heteroaromatic rings; or C₁-C₁₀ alkylether, amino, hydrazido, C₁-C₁₀ alkylamino, C₁-C₁₀ alkoxy, C₁-C₁₀-alkoxycarbonyl, C₁-C₁₀ alkanol, C₁-C₁₀ acyl, C₁-C₁₀ thioalkoxy, pyridylthio, thio, and C₁-C₁₀ alkylthio, acetoamido, sulfonic acid;

- 45 -

and pharmaceutically acceptable salts thereof;

for the preparation of a pharmaceutical composition for the treatment of a condition which requires for said treatment modulation of A₃ adenosine receptor (A₃AR).

2. The use as claimed in Claim 1, wherein said R₂ is selected from H, n-pentyl, or a five membered heterocyclic aromatic ring having the following formula (IV):



(IV)

wherein Z is selected from O, S or NH, preferably O.

3. The composition as claimed in Claim 1 or 2, wherein said A₃RM is an A₃ adenosine receptor activator.
4. The use as claimed in any one of Claims 1 to 3, wherein A₃RM is an imidazoquinoline derivative selected from:

N-(4-Methyl-phenyl)-2-cyclopentyl-1H-imidazo[4,5-c]quinolin-4-amine
 N-(4-Methoxy-phenyl)-2-cyclopentyl-1H-imidazo[4,5-c]quinolin-4-amine
 N-(3,4-Dichloro-phenyl)-2-cyclopentyl-1H-imidazo[4,5-c]quinolin-4-amine
 N-(4-Chloro-phenyl)-2-cyclopentyl-1H-imidazo[4,5-c]quinolin-4-amine
 N-(3-Methanol-phenyl)-2-cyclopentyl-1H-imidazo[4,5-c]quinolin-4-amine
 N-([3,4-c]Indan)-2-cyclopentyl-1H-imidazo[4,5-c]quinolin-4-amine
 N-(1H-indazol-6-yl)-2-cyclopentyl-1H-imidazo[4,5-c]quinolin-4-amine
 N-(4-Methoxy-benzyl)-2-cyclopentyl-1H-imidazo[4,5-c]quinolin-4-amine
 N-(1H-Indol-6-yl)-2-cyclopentyl-1H-imidazo[4,5-c]quinolin-4-amine
 N-(Benzyl)-2-cyclopentyl-1H-imidazo[4,5-c]quinolin-4-amine
 N-(Phenylethyl)-2-cyclopentyl-1H-imidazo[4,5-c]quinolin-4-amine
 N-(3,4-Dichloro-phenyl)-2-cycloheptyl-1H-imidazo[4,5-c]quinolin-4-amine
 N-(3,4-Dichloro-phenyl)-2-furyl-1H-imidazo[4,5-c]quinolin-4-amine
 N-(3,4-Dichloro-phenyl)-2-cyclobutyl-1H-imidazo[4,5-c]quinolin-4-amine
 N-(3,4-Dichloro-phenyl)-2-cyclohexyl-1H-imidazo[4,5-c]quinolin-4-amine
 N-(3,4-Dichloro-phenyl)-2--1H-imidazo[4,5-c]quinolin-4-amine

- 46 -

N-(3,4-Dichloro-phenyl)-2-pentyl-1H-imidazo[4,5-c]quinolin-4-amine.

5. The use as claimed in Claim 4, wherein said imidazoquinoline derivative is selected from:

N-(3,4-Dichloro-phenyl)-2-cyclopentyl-1H-imidazo[4,5-c]quinolin-4-amine;
N-(3,4-Dichloro-phenyl)-2-cycloheptyl-1H-imidazo[4,5-c]quinolin-4-amine;
N-(3,4-Dichloro-phenyl)-2-cyclobutyl-1H-imidazo[4,5-c]quinolin-4-amine; and
N-(3,4-Dichloro-phenyl)-2-cyclohexyl-1H-imidazo[4,5-c]quinolin-4-amine.

6. The use as claimed in Claim 4, wherein said imidazoquinoline derivative is N-(3,4-Dichloro-phenyl)-2-cyclohexyl-1H-imidazo[4,5-c]quinolin-4-amine.

7. The use as claimed in any one of Claims 3 to 5, for the preparation of a pharmaceutical composition for enhancing or stimulating A₃AR.

8. The use of Claim 7, wherein said enhancement is exhibited by the occurrence of one or more of the following:

- (a) an increase of at least 15% in the efficacy of said A₃AR by binding of said A₃M to the allosteric site of said A₃AR; or
- (b) a decrease in dissociation rate of adenosine or an A₃AR agonist to the its binding site.

9. The use as claimed in any one of Claims 1 to 8, for the preparation of a composition in a form suitable for oral administration.


10. The use as claimed in any one of Claims 3 to 9, for the preparation of a composition for the treatment of a condition which requires for said treatment modulation of A₃ adenosine receptor (A₃AR) is selected from one or more of a malignancy, an immuno-compromised affliction, and condition associated with high intraocular pressure.

11. The use as claimed in any one of Claims 1 to 10, wherein said A₃RM is combined with a ligand to the orthosteric binding site of said A₃R.

12. The use as claimed in Claim 11, wherein said ligand is an A₃R agonist and said A₃AM is an A₃ adenosine receptor allosteric activator.

- 47 -

13. The use as claimed in any one of Claims 1 to 12, for the preparation of a composition for the treatment of rheumatoid arthritis.
14. The use as claimed in any one of Claims 1 to 12, for the preparation of a composition for enhancing a subject's myeloid system.
15. A method of modulating A₃ adenosine receptor (A₃AR) in a subject, the method comprises administering to said subject an amount of an A₃ adenosine receptor allosteric modulator (A₃RM), the amount being effective to modulate A₃AR activity, wherein said A₃RM has the following general formula (I):



Formula I

wherein:

R₁ represents an aryl or alkaryl being optionally substituted at the aromatic ring once or more with a substituent selected C₁-C₁₀ alkyl, halo, C₁-C₁₀ alkanol, hydroxyl, C₁-C₁₀ acyl, C₁-C₁₀ alkoxy; C₁-C₁₀-alkoxycarbony, C₁-C₁₀ alkoxyalkyl; C₁-C₁₀ thioalkoxy; C₁-C₁₀ alkylether, amino, hydrazido, C₁-C₁₀ alkylamino, pyridylthio, C₂-C₁₀ alkenyl; C₂-C₁₀ alkynyl, thio, and C₁-C₁₀ alkylthio, acetoamido, sulfonic acid; or said substituents can form together a cycloalkyl or cycloalkenyl fused to said aryl, the cycloalkyl or cycloalkenyl optionally comprising one or more heteroatoms; provided that said aryl is not an unsubstituted phenyl group;


- R₂ represents hydrogen or a substituent selected from C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl; C₂-C₁₀ alkynyl, C₄-C₁₀ cycloalkyl, C₄-C₁₀ cycloalkenyl or a five to

- 48 -

seven membered heterocyclic aromatic ring, C₅-C₁₅ fused cycloalkyl, bicyclic aromatic or heteroaromatic rings; or C₁-C₁₀ alkylether, amino, hydrazido, C₁-C₁₀ alkylamino, C₁-C₁₀ alkoxy, C₁-C₁₀-alkoxycarbony, C₁-C₁₀ alkanol, C₁-C₁₀ acyl, C₁-C₁₀ thioalkoxy, pyridylthio, thio, and C₁-C₁₀ alkylthio, acetoamido, sulfonic acid;

and pharmaceutically acceptable salts thereof.

16. A method of treating a subject for a condition which requires for said treatment modulation of A₃ adenosine receptor (A₃AR), the method comprises administering to said subject an amount of an A₃ adenosine receptor allosteric modulator (A₃RM), the amount being effective to modulate A₃AR activity, wherein said A₃AR allosteric modulator having the following general formula (I):



Formula I

- wherein:

- **R₁** represents an aryl or alkaryl being optionally substituted at the aromatic ring once or more with a substituent selected C₁-C₁₀ alkyl, halo, C₁-C₁₀ alkanol, hydroxyl, C₁-C₁₀ acyl, C₁-C₁₀ alkoxy; C₁-C₁₀-alkoxycarbony, C₁-C₁₀ alkoxyalkyl; C₁-C₁₀ thioalkoxy; C₁-C₁₀ alkylether, amino, hydrazido, C₁-C₁₀ alkylamino, pyridylthio, C₂-C₁₀ alkenyl; C₂-C₁₀ alkynyl, thio, and C₁-C₁₀ alkylthio, acetoamido, sulfonic acid; or said substituents can form together a cycloalkyl or cycloalkenyl fused to said aryl, the cycloalkyl or cycloalkenyl

- 49 -

optionally comprising one or more heteroatoms; provided that said aryl is not an unsubstituted phenyl group;

- R_2 represents hydrogen or a substituent selected from C_1 - C_{10} alkyl, C_2 - C_{10} alkenyl; C_2 - C_{10} alkynyl, C_4 - C_{10} cycloalkyl, C_4 - C_{10} cycloalkenyl or a five to seven membered heterocyclic aromatic ring, C_5 - C_{15} fused cycloalkyl, bicyclic aromatic or heteroaromatic rings; or C_1 - C_{10} alkylether, amino, hydrazido, C_1 - C_{10} alkylamino, C_1 - C_{10} alkoxy, C_1 - C_{10} -alkoxycarbony, C_1 - C_{10} alkanol, C_1 - C_{10} acyl, C_1 - C_{10} thioalkoxy, pyridylthio, thio, and C_1 - C_{10} alkylthio, acetoamido, sulfonic acid;

and pharmaceutically acceptable salts thereof.

17. The method as claimed in Claim 15 or 16, wherein said A3AM is as defined in any one of Claims 1 to 14.

18. An imidazoquinoline derivative selected from the following:

N-(4-Methyl-phenyl)-2-cyclopentyl-1H-imidazo[4,5-c]quinolin-4-amine
 N-(4-Methoxy-phenyl)-2-cyclopentyl-1H-imidazo[4,5-c]quinolin-4-amine
 N-(3,4-Dichloro-phenyl)-2-cyclopentyl-1H-imidazo[4,5-c]quinolin-4-amine
 N-(4-Chloro-phenyl)-2-cyclopentyl-1H-imidazo[4,5-c]quinolin-4-amine
 N-(3-Methanol-phenyl)-2-cyclopentyl-1H-imidazo[4,5-c]quinolin-4-amine
 N-([3,4-c]Indan)-2-cyclopentyl-1H-imidazo[4,5-c]quinolin-4-amine
 N-(1H-indazol-6-yl)-2-cyclopentyl-1H-imidazo[4,5-c]quinolin-4-amine
 N-(4-Methoxy-benzyl)-2-cyclopentyl-1H-imidazo[4,5-c]quinolin-4-amine
 N-(1H-Indol-6-yl)-2-cyclopentyl-1H-imidazo[4,5-c]quinolin-4-amine
 N-(Benzyl)-2-cyclopentyl-1H-imidazo[4,5-c]quinolin-4-amine
 N-(Phenylethyl)-2-cyclopentyl-1H-imidazo[4,5-c]quinolin-4-amine
 N-(3,4-Dichloro-phenyl)-2-cycloheptyl-1H-imidazo[4,5-c]quinolin-4-amine
 N-(3,4-Dichloro-phenyl)-2-furyl-1H-imidazo[4,5-c]quinolin-4-amine
 N-(3,4-Dichloro-phenyl)-2-cyclobutyl-1H-imidazo[4,5-c]quinolin-4-amine
 N-(3,4-Dichloro-phenyl)-2-cyclohexyl-1H-imidazo[4,5-c]quinolin-4-amine
 N-(3,4-Dichloro-phenyl)-2--1H-imidazo[4,5-c]quinolin-4-amine
 N-(3,4-Dichloro-phenyl)-2-pentyl-1H-imidazo[4,5-c]quinolin-4-amine.


19. An imidazoquinoline derivative selected from:

- 50 -

N-(3,4-Dichloro-phenyl)-2-cyclopentyl-1H-imidazo[4,5-c]quinolin-4-amine;
 N-(3,4-Dichloro-phenyl)-2-cycloheptyl-1H-imidazo[4,5-c]quinolin-4-amine;
 N-(3,4-Dichloro-phenyl)-2-cyclobutyl-1H-imidazo[4,5-c]quinolin-4-amine; and
 N-(3,4-Dichloro-phenyl)-2-cyclohexyl-1H-imidazo[4,5-c]quinolin-4-amine.

20. A pharmaceutical composition comprising as active ingredient the imidazoquinoline derivative as claimed in Claim 18 or 19.

21. A compound of general formula (I) having the following general formula (I):



Formula I

wherein:

- R_1 represents an aryl or alkaryl being optionally substituted at the aromatic ring once or more with a substituent selected C_1 - C_{10} alkyl, halo, C_1 - C_{10} alkanol, hydroxyl, C_1 - C_{10} acyl, C_1 - C_{10} alkoxy; C_1 - C_{10} -alkoxycarbony, C_1 - C_{10} alkoxyalkyl; C_1 - C_{10} thioalkoxy; C_1 - C_{10} alkylether, amino, hydrazido, C_1 - C_{10} alkylamino, pyridylthio, C_2 - C_{10} alkenyl; C_2 - C_{10} alkynyl, thio, and C_1 - C_{10} alkylthio, acetoamido, sulfonic acid; or said substituents can form together a cycloalkyl or cycloalkenyl fused to said aryl, the cycloalkyl or cycloalkenyl optionally comprising one or more heteroatoms; provided that said aryl is not an unsubstituted phenyl group;


- R_2 represents hydrogen or a substituent selected from C_1 - C_{10} alkyl, C_2 - C_{10} alkenyl; C_2 - C_{10} alkynyl, C_4 - C_{10} cycloalkyl, C_4 - C_{10} cycloalkenyl or a five to seven membered heterocyclic aromatic ring, C_5 - C_{15} fused cycloalkyl, bicyclic aromatic or heteroaromatic rings; or C_1 - C_{10} alkylether, amino, hydrazido, C_1 - C_{10}

- 51 -

alkylamino, C₁-C₁₀ alkoxy, C₁-C₁₀-alkoxycarbony, C₁-C₁₀ alkanol, C₁-C₁₀ acyl, C₁-C₁₀ thioalkoxy, pyridylthio, thio, and C₁-C₁₀ alkylthio, acetoamido, sulfonic acid;

and pharmaceutically acceptable salts thereof for use as an A₃ adenosine receptor allosteric modulator (A₃RM).

22. A pharmaceutical composition for the treatment of a condition which requires modulation of A₃ adenosine receptor (A₃AR), comprising as active ingredient an A₃ adenosine receptor allosteric modulator (A₃RM) having the following general formula (I):



Formula I

- wherein:
- **R₁** represents an aryl or alkaryl being optionally substituted at the aromatic ring once or more with a substituent selected C₁-C₁₀ alkyl, halo, C₁-C₁₀ alkanol, hydroxyl, C₁-C₁₀ acyl, C₁-C₁₀ alkoxy; C₁-C₁₀-alkoxycarbony, C₁-C₁₀ alkoxyalkyl; C₁-C₁₀ thioalkoxy; C₁-C₁₀ alkylether, amino, hydrazido, C₁-C₁₀ alkylamino, pyridylthio, C₂-C₁₀ alkenyl; C₂-C₁₀ alkynyl, thio, and C₁-C₁₀ alkylthio, acetoamido, sulfonic acid; or said substituents can form together a cycloalkyl or cycloalkenyl fused to said aryl, the cycloalkyl or cycloalkenyl optionally comprising one or more heteroatoms; provided that said aryl is not an unsubstituted phenyl group;
- **R₂** represents hydrogen or a substituent selected from C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl; C₂-C₁₀ alkynyl, C₄-C₁₀ cycloalkyl, C₄-C₁₀ cycloalkenyl or a five to

- 52 -

seven membered heterocyclic aromatic ring, C₅-C₁₅ fused cycloalkyl, bicyclic aromatic or heteroaromatic rings; or C₁-C₁₀ alkylether, amino, hydrazido, C₁-C₁₀ alkylamino, C₁-C₁₀ alkoxy, C₁-C₁₀-alkoxycarbony, C₁-C₁₀ alkanol, C₁-C₁₀ acyl, C₁-C₁₀ thioalkoxy, pyridylthio, thio, and C₁-C₁₀ alkylthio, acetoamido, sulfonic acid;

and pharmaceutically acceptable salts thereof.

23. The pharmaceutical composition as claimed in Claim 22, wherein said A₃AM is as defined in any one of Claims 1 to 14.

1/3




FIGURE 1

2/3




FIGURE 2A




FIGURE 2B

3/3




FIGURE 3

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2007/001930

A. CLASSIFICATION OF SUBJECT MATTER
 INV. A61K31/4745 A61K31/00 A61P35/00 A61P37/00 C07D471/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED
 Minimum documentation searched (classification system followed by classification symbols)
A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
EPO-Internal, EMBASE, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>GALEN VAN P J M ET AL: "1H-IMIDAZO[4,5-]QUINOLIN-4-AMINES: NOVEL NON-XANTHINE ADENOSINE ANTAGONISTS" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 34, no. 3, 1991, pages 1202-1206, XP002024865 ISSN: 0022-2623 CAS-RN: 132206-96-3, 132206-97-4, 132207-06-8, 132207-07-9, 132207-08-0 page 1202, column 1, paragraph 1 page 1205, column 2, paragraph 3 ----- -/--</p>	3, 21-23

Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents :

A document defining the general state of the art which is not considered to be of particular relevance	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
E earlier document but published on or after the international filing date	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
O document referring to an oral disclosure, use, exhibition or other means	* & * document member of the same patent family
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search 3 July 2007	Date of mailing of the international search report 16/07/2007
---	---

Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer Kerkmann, Miren
---	--

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2007/001930

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>ADENOT M ET AL: "Interest of cluster significance analysis in structure-affinity relationships for non-xanthine heterocyclic antagonists of adenosine" EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, EDITIONS SCIENTIFIQUE ELSEVIER, PARIS, FR, vol. 32, no. 6, 1997, pages 493-504, XP002229258 ISSN: 0223-5234 CAS-RN: 132207-06-8, 132207-08-0 page 493, column 2, paragraph 2 page 504, column 1, paragraph 1 -----</p>	3,21-23
X	<p>IJZERMAN, A. P. ET AL: "Molecular modeling of the antagonist binding site on the adenosine A1 receptor" NUCLEOSIDES & NUCLEOTIDES , 10(5), 1039-47 CODEN: NUNUD5; ISSN: 0732-8311, 1991, XP008080054 CAS-RN: 132207-06-8, 132207-07-9, 132207-08-0 page 1039, last paragraph page 1046, paragraphs 2,3 -----</p>	3,21-23
X	<p>NEUWELS, M.: "Approach to an adenosine pharmacophore by molecular modeling" JOURNAL DE PHARMACIE DE BELGIQUE , 47(4), 351-63 CODEN: JPBEAJ; ISSN: 0047-2166, 1992, XP008080052 CAS-RN: 132207-06-8 page 352, column 2, paragraphs 2,3 page 353; figure 2 page 362, column 1, paragraph 3 - column 2, paragraph 2 -----</p>	3,21-23
X	<p>FOSSA, PAOLA ET AL: "New pyrazolo[3,4-b]pyridones as selective A1 adenosine receptor antagonists: Synthesis, biological evaluation and molecular modeling studies" ORGANIC & BIOMOLECULAR CHEMISTRY , 3(12), 2262-2270 CODEN: OBCRAK; ISSN: 1477-0520, 2005, XP002439522 CAS-RN: 132207-06-8 page 2262, column 1, paragraph 2 - column 2, paragraph 2 page 2266; table 2; compound 57 ----- -/--</p>	3,21-23

INTERNATIONAL SEARCH REPORT

International application No

PCT/US2007/001930

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>GAO, ZHAN-GUO ET AL: "Selective allosteric enhancement of agonist binding and function at human A3 adenosine receptors by a series of imidazoquinoline derivatives"</p> <p>MOLECULAR PHARMACOLOGY, 62(1), 81-89 CODEN: MOPMA3; ISSN: 0026-895X, 2002, XP002439523 abstract page 82, column 1, paragraph 2 page 82; figure 1 page 88, column 1, paragraph 2 page 88, column 2, paragraph 2-4</p>	1-23
Y	<p>BAHARAV EE ET AL: "Antiinflammatory effect of A3 adenosine receptor agonists in murine autoimmune arthritis models"</p> <p>JOURNAL OF RHEUMATOLOGY, TORONTO, CA, vol. 32, no. 3, 2005, pages 469-476, XP008060306 ISSN: 0315-162X abstract page 469, column 2, last paragraph - page 470, column 1, paragraph 1 page 475, column 1, paragraph 1 - column 2, paragraph 2</p>	1-23
Y	<p>FISHMAN P ET AL: "TARGETING THE A3 ADENOSINE RECEPTOR FOR CANCER THERAPY: INHIBITION OF PROSTATE CARCINOMA CELL GROWTH BY A3AR AGONIST"</p> <p>ANTICANCER RESEARCH, HELENIC ANTICANCER INSTITUTE, ATHENS,, GR, vol. 23, no. 3A, May 2003 (2003-05), pages 2077-2084, XP008048649 ISSN: 0250-7005 abstract page 2077, column 2, paragraph 1 page 2081, column 2, paragraph 1 page 2082, column 2, paragraph 1</p>	1-23
P,X	<p>GOBLYOS A ET AL: "Structure-activity relationships of new 1H-imidazo[4,5-c]quinolin-4- amine derivatives as allosteric enhancers of the A3 adenosine receptor"</p> <p>JOURNAL OF MEDICINAL CHEMISTRY 01 JUN 2006 UNITED STATES, vol. 49, no. 11, 1 June 2006 (2006-06-01), pages 3354-3361, XP002439524 ISSN: 0022-2623 page 3354, column 1, paragraph 1 page 3355, column 1, paragraph 3 page 3356; table 1 page 3358, column 1, last paragraph</p>	1-23

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US2007/001930

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 15-17 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
- No protest accompanied the payment of additional search fees.